Document_and_Entity_Informatio
Document and Entity Information Document | 9 Months Ended |
Dec. 31, 2013 | |
Document And Entity Information [Abstract] | ' |
Entity Registrant Name | 'MCKESSON CORP |
Entity Central Index Key | '0000927653 |
Current Fiscal Year End Date | '--03-31 |
Entity Filer Category | 'Large Accelerated Filer |
Document Type | '10-Q |
Document Period End Date | 31-Dec-13 |
Document Fiscal Year Focus | '2014 |
Document Fiscal Period Focus | 'Q3 |
Amendment Flag | 'false |
Entity Common Stock, Shares Outstanding | 230,126,791 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements Of Operations (USD $) | 3 Months Ended | 9 Months Ended | ||||||
In Millions, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | ||||
Income Statement [Abstract] | ' | ' | ' | ' | ||||
Revenues | $34,306 | $31,099 | $99,468 | $91,553 | ||||
Cost of Sales | -32,466 | -29,454 | -93,699 | -86,664 | ||||
Gross Profit | 1,840 | 1,645 | 5,769 | 4,889 | ||||
Operating Expenses | -1,337 | -1,147 | -3,890 | -3,230 | ||||
Litigation Charges | -18 | 0 | -68 | -60 | ||||
Gain on business combination | 0 | 0 | 0 | 81 | ||||
Total Operating Expenses | -1,355 | -1,147 | -3,958 | -3,209 | ||||
Operating Income | 485 | 498 | 1,811 | 1,680 | ||||
Other Income (Loss), Net | -8 | 10 | 7 | 28 | ||||
Interest Expense | -69 | -59 | -187 | -170 | ||||
Income from Continuing Operations Before Income Taxes | 408 | 449 | 1,631 | 1,538 | ||||
Income Tax Expense | -252 | -143 | -639 | -454 | ||||
Income from Continuing Operations | 156 | 306 | 992 | 1,084 | ||||
Loss from discontinued operations, net of tax | -92 | -8 | -100 | -5 | ||||
Net Income | $64 | $298 | $892 | $1,079 | ||||
Diluted | ' | ' | ' | ' | ||||
Continuing operations | $0.67 | [1] | $1.27 | [1] | $4.26 | [1] | $4.51 | [1] |
Discontinued operations | ($0.39) | [1] | ($0.03) | [1] | ($0.43) | [1] | ($0.02) | [1] |
Total | $0.28 | [1] | $1.24 | [1] | $3.83 | [1] | $4.49 | [1] |
Basic | ' | ' | ' | ' | ||||
Continuing operations | $0.68 | [1] | $1.30 | [1] | $4.34 | [1] | $4.60 | [1] |
Discontinued operations | ($0.40) | [1] | ($0.03) | [1] | ($0.44) | [1] | ($0.02) | [1] |
Total | $0.28 | [1] | $1.27 | [1] | $3.90 | [1] | $4.58 | [1] |
Dividends Declared Per Common Share | $0.24 | $0.20 | $0.68 | $0.60 | ||||
Weighted Average Common Shares | ' | ' | ' | ' | ||||
Diluted | 234 | 240 | 233 | 240 | ||||
Basic | 230 | 235 | 229 | 236 | ||||
[1] | Certain computations may reflect rounding adjustments. |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Comprehensive Income (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Statement of Comprehensive Income [Abstract] | ' | ' | ' | ' |
Net Income | $64 | $298 | $892 | $1,079 |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | ' | ' | ' | ' |
Foreign currency translation adjustments, net of income tax expense (benefit) of nil, ($4), $24 and ($2) | -55 | -16 | -16 | 14 |
Unrealized gains (losses) on cash flow hedges, net of income tax expense of nil, nil, nil and nil | -1 | 0 | -2 | 2 |
Retirement-related benefit plans, net of income tax expense of $4, $3, $11 and $8 | 4 | 5 | 15 | 14 |
Other Comprehensive Income (Loss), Net of Tax | -52 | -11 | -3 | 30 |
Comprehensive Income | $12 | $287 | $889 | $1,109 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Statement of Comprehensive Income [Abstract] | ' | ' | ' | ' |
Foreign currency translation adjustments, income tax expense (benefit) of nil, ($4), $24 and ($2) | $0 | ($4) | $24 | ($2) |
Unrealized gains (losses) on cash flow hedges and other, income tax expense of nil, nil, nil and nil | 0 | 0 | 0 | 0 |
Retirement-related benefit plans, income tax expense of $4, $3, $11 and $8 | $4 | $3 | $11 | $8 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Mar. 31, 2013 |
In Millions, unless otherwise specified | ||
Current Assets | ' | ' |
Cash and cash equivalents | $2,431 | $2,456 |
Receivables, net | 10,750 | 9,975 |
Inventories, net | 11,462 | 10,335 |
Prepaid expenses and other | 591 | 404 |
Total Current Assets | 25,234 | 23,170 |
Property, Plant and Equipment, Net | 1,359 | 1,321 |
Goodwill | 6,300 | 6,405 |
Intangible Assets, Net | 2,066 | 2,270 |
Other Assets | 1,520 | 1,620 |
Total Assets | 36,479 | 34,786 |
Current Liabilities | ' | ' |
Drafts and accounts payable | 16,638 | 16,108 |
Deferred revenue | 1,286 | 1,359 |
Deferred tax liabilities | 1,519 | 1,626 |
Current portion of long-term debt | 353 | 352 |
Other accrued liabilities | 2,108 | 1,912 |
Total Current Liabilities | 21,904 | 21,357 |
Long-Term Debt | 4,521 | 4,521 |
Other Noncurrent Liabilities | 2,027 | 1,838 |
Commitments and Contingent Liabilities (Note 13) | ' | ' |
Stockholders' Equity | ' | ' |
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding | 0 | 0 |
Common stock, $0.01 par value, 800 shares authorized at December 31, 2013 and March 31, 2013, 380 and 376 shares issued at December 31, 2013 and March 31, 2013 | 4 | 4 |
Additional Paid-in Capital | 6,442 | 6,078 |
Retained Earnings | 11,138 | 10,402 |
Accumulated Other Comprehensive Loss | -68 | -65 |
Other | 16 | 14 |
Treasury Shares, at Cost, 150 and 149 at December 31, 2013 and March 31, 2013 | -9,505 | -9,363 |
Total Stockholders' Equity | 8,027 | 7,070 |
Total Liabilities and Stockholders' Equity | $36,479 | $34,786 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Parentheticals) (USD $) | Dec. 31, 2013 | Mar. 31, 2013 |
In Millions, except Per Share data, unless otherwise specified | ||
Stockholders' Equity | ' | ' |
Preferred stock, par value | $0.01 | $0.01 |
Preferred stock, shares authorized | 100 | 100 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 800 | 800 |
Common stock, shares issued | 380 | 376 |
Treasury stock, shares | 150 | 149 |
Condensed_Consolidated_Stateme3
Condensed Consolidated Statements Of Cash Flows (USD $) | 9 Months Ended | |
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Operating Activities | ' | ' |
Net income | $892 | $1,079 |
Adjustments to reconcile to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 475 | 383 |
Deferred taxes | 86 | 499 |
Share-based compensation expense | 115 | 123 |
Gain on business combination | 0 | -81 |
Charges associated with last-in-first-out inventory method | 186 | 5 |
Other non-cash items | 83 | 49 |
Changes in operating assets and liabilities, net of acquisitions: | ' | ' |
Receivables | -865 | 67 |
Inventories | -1,387 | -313 |
Drafts and accounts payable | 584 | -1,078 |
Deferred revenue | 20 | 72 |
Taxes | 154 | -90 |
Litigation charges | 68 | 60 |
Litigation settlement payments | -86 | -470 |
Other | 147 | -29 |
Net cash provided by operating activities | 472 | 276 |
Investing Activities | ' | ' |
Property acquisitions | -188 | -145 |
Capitalized software expenditures | -108 | -111 |
Acquisitions, less cash and cash equivalents acquired | -116 | -577 |
Proceeds from sale of business | 55 | 0 |
Other | -65 | 49 |
Net cash used in investing activities | -422 | -784 |
Financing Activities | ' | ' |
Proceeds from short-term borrowings | 150 | 1,125 |
Repayments of short-term borrowings | -150 | -1,525 |
Proceeds from issuances of long-term debt | 0 | 892 |
Common stock transactions: | ' | ' |
Issuances | 150 | 112 |
Share repurchases, including shares surrendered for tax withholding | -128 | -413 |
Dividends paid | -154 | -147 |
Other | 59 | 38 |
Net cash provided by (used in) financing activities | -73 | 82 |
Effect of exchange rate changes on cash and cash equivalents | -2 | 3 |
Net increase (decrease) in cash and cash equivalents | -25 | -423 |
Cash and cash equivalents at beginning of period | 2,456 | 3,149 |
Cash and cash equivalents at end of period | $2,431 | $2,726 |
Significant_Accounting_Policie
Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2013 | |
Accounting Policies [Abstract] | ' |
Significant Accounting Policies | ' |
Significant Accounting Policies | |
Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. We also evaluate our ownership, contractual and other interests in entities to determine if they are variable interest entities (“VIEs”), if we have a variable interest in those entities and the nature and extent of those interests. These evaluations are highly complex and involve judgment and the use of estimates and assumptions based on available historical information and management’s judgment, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. The consolidated VIEs are not material to our condensed consolidated financial statements. Intercompany transactions and balances have been eliminated. The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. | |
To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented. | |
The results of operations for the quarter and nine months ended December 31, 2013 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013 previously filed with the SEC on May 7, 2013 (“2013 Annual Report”). | |
Certain prior period amounts, which primarily relate to discontinued operations, have been reclassified to conform to the current period presentation. Refer to Financial Note 7, “Discontinued Operations,” for more information. | |
The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year. | |
Recently Adopted Accounting Pronouncements | |
Balance Sheet Offsetting: In the first quarter of 2014, we adopted disclosure guidance on a retrospective basis related to the offsetting of assets and liabilities. The guidance requires an entity to disclose information about offsetting assets and liabilities for derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific GAAP criteria or subject to a master netting arrangement or similar agreement. The adoption of this guidance did not have a material effect on our condensed consolidated financial statements. | |
Comprehensive Income: In the first quarter of 2014, we adopted disclosure guidance on a prospective basis related to the reporting of amounts reclassified out of Accumulated Other Comprehensive Income ("AOCI”). The guidance requires disclosure of amounts reclassified out of AOCI by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. The adoption of this guidance did not have a material effect on our condensed consolidated financial statements. | |
Recently Issued Accounting Pronouncement Not Yet Adopted | |
Cumulative Translation Adjustments: In March 2013, amended guidance was issued for a parent’s accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or group of assets within a foreign entity or of an investment in a foreign entity. The amended guidance requires the release of any cumulative translation adjustment into net income only upon complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity. Also, it requires the release of all or a pro rata portion of the cumulative translation adjustment to net income in case of sale of an equity method investment that is a foreign entity. The amended guidance is applicable to us effective in the first quarter of fiscal 2015. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements. |
Business_Combinations
Business Combinations | 9 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Business Combinations [Abstract] | ' | |||||||||||
Business combinations | ' | |||||||||||
Business Combinations | ||||||||||||
On February 22, 2013, we acquired all of the outstanding shares of PSS World Medical, Inc. (“PSS World Medical”) of Jacksonville, Florida for $29.00 per share plus the assumption of PSS World Medical’s debt, or approximately $1.9 billion in aggregate, consisting of cash consideration of $1.3 billion, net of cash acquired, and the assumption of long-term debt with a fair value of $0.6 billion. The cash paid at acquisition was funded from cash on hand and the issuance of long-term debt. PSS World Medical markets and distributes medical products and services throughout the United States. The acquisition of PSS World Medical expands our existing Medical-Surgical business. | ||||||||||||
The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date: | ||||||||||||
(In millions) | Amounts | Measurement | Amounts | |||||||||
Previously | Period | Recognized as of | ||||||||||
Recognized as of | Adjustments | Acquisition Date | ||||||||||
Acquisition Date | (Provisional as | |||||||||||
(Provisional)(1) | Adjusted) | |||||||||||
Current assets, net of cash and cash equivalents acquired | $ | 706 | $ | 5 | $ | 711 | ||||||
Goodwill | 1,145 | (15 | ) | 1,130 | ||||||||
Intangible assets | 557 | 11 | 568 | |||||||||
Other long-term assets | 183 | (1 | ) | 182 | ||||||||
Current liabilities | (376 | ) | 3 | (373 | ) | |||||||
Current portion of long-term debt | (635 | ) | — | (635 | ) | |||||||
Other long-term liabilities | (281 | ) | (3 | ) | (284 | ) | ||||||
Net assets acquired, less cash and cash equivalents | $ | 1,299 | $ | — | $ | 1,299 | ||||||
-1 | As previously reported in our Form 10-K for the year ended March 31, 2013. | |||||||||||
During the first nine months of 2014, the fair value measurements of assets acquired and liabilities assumed of PSS World Medical as of the acquisition date were refined. This refinement did not have a significant impact on our condensed consolidated statements of operations, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. These amounts are subject to change within the measurement period as our fair value assessments are finalized. Financial results for PSS World Medical have been included in the results of operations within our Medical-Surgical distribution and services business, which is part of our Distribution Solutions segment since the date of acquisition. | ||||||||||||
On April 6, 2012, we purchased the remaining 50% ownership interest in our corporate headquarters building located in San Francisco, California, for $90 million, which was funded from cash on hand. We previously held a 50% ownership interest and were the primary tenant in this building. This transaction was accounted for as a step acquisition, which required that we re-measure our previously held 50% ownership interest to fair value and record the difference between the fair value and carrying value as a gain in the consolidated statements of operations. The re-measurement to fair value resulted in a non-cash pre-tax gain of $81 million ($51 million after-tax), which was recorded as a gain on business combination within Corporate operating expenses in the consolidated statements of operations during the first quarter of 2013. | ||||||||||||
The total fair value of the net assets acquired was $180 million, which was allocated as follows: building and improvements of $113 million and land of $58 million, with the remainder allocated for settlement of our pre-existing lease and lease intangible assets. The fair value of the building and improvements was determined based on current market replacement costs less depreciation and unamortized tenant improvement costs, as well as other relevant market information, which are considered to be Level 3 inputs under the fair value measurements and disclosure guidance. The building and improvements have a weighted average useful life of 30 years. The fair value of the land was determined using comparable sales of land within the surrounding market, which is considered to be a Level 2 input. | ||||||||||||
During the last two years, we also completed a number of smaller acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition. | ||||||||||||
Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes. The pro forma results of operations for our business acquisitions and the results of operations for these acquisitions since the acquisition date have not been presented because the effects were not material to the consolidated financial statements on either an individual or an aggregate basis. |
Acquisition_of_Celesio_AG_Note
Acquisition of Celesio AG (Notes) | 9 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Business Acquisition [Line Items] | ' | |||||||||||
Acquisition of Celesio AG | ' | |||||||||||
Business Combinations | ||||||||||||
On February 22, 2013, we acquired all of the outstanding shares of PSS World Medical, Inc. (“PSS World Medical”) of Jacksonville, Florida for $29.00 per share plus the assumption of PSS World Medical’s debt, or approximately $1.9 billion in aggregate, consisting of cash consideration of $1.3 billion, net of cash acquired, and the assumption of long-term debt with a fair value of $0.6 billion. The cash paid at acquisition was funded from cash on hand and the issuance of long-term debt. PSS World Medical markets and distributes medical products and services throughout the United States. The acquisition of PSS World Medical expands our existing Medical-Surgical business. | ||||||||||||
The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date: | ||||||||||||
(In millions) | Amounts | Measurement | Amounts | |||||||||
Previously | Period | Recognized as of | ||||||||||
Recognized as of | Adjustments | Acquisition Date | ||||||||||
Acquisition Date | (Provisional as | |||||||||||
(Provisional)(1) | Adjusted) | |||||||||||
Current assets, net of cash and cash equivalents acquired | $ | 706 | $ | 5 | $ | 711 | ||||||
Goodwill | 1,145 | (15 | ) | 1,130 | ||||||||
Intangible assets | 557 | 11 | 568 | |||||||||
Other long-term assets | 183 | (1 | ) | 182 | ||||||||
Current liabilities | (376 | ) | 3 | (373 | ) | |||||||
Current portion of long-term debt | (635 | ) | — | (635 | ) | |||||||
Other long-term liabilities | (281 | ) | (3 | ) | (284 | ) | ||||||
Net assets acquired, less cash and cash equivalents | $ | 1,299 | $ | — | $ | 1,299 | ||||||
-1 | As previously reported in our Form 10-K for the year ended March 31, 2013. | |||||||||||
During the first nine months of 2014, the fair value measurements of assets acquired and liabilities assumed of PSS World Medical as of the acquisition date were refined. This refinement did not have a significant impact on our condensed consolidated statements of operations, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. These amounts are subject to change within the measurement period as our fair value assessments are finalized. Financial results for PSS World Medical have been included in the results of operations within our Medical-Surgical distribution and services business, which is part of our Distribution Solutions segment since the date of acquisition. | ||||||||||||
On April 6, 2012, we purchased the remaining 50% ownership interest in our corporate headquarters building located in San Francisco, California, for $90 million, which was funded from cash on hand. We previously held a 50% ownership interest and were the primary tenant in this building. This transaction was accounted for as a step acquisition, which required that we re-measure our previously held 50% ownership interest to fair value and record the difference between the fair value and carrying value as a gain in the consolidated statements of operations. The re-measurement to fair value resulted in a non-cash pre-tax gain of $81 million ($51 million after-tax), which was recorded as a gain on business combination within Corporate operating expenses in the consolidated statements of operations during the first quarter of 2013. | ||||||||||||
The total fair value of the net assets acquired was $180 million, which was allocated as follows: building and improvements of $113 million and land of $58 million, with the remainder allocated for settlement of our pre-existing lease and lease intangible assets. The fair value of the building and improvements was determined based on current market replacement costs less depreciation and unamortized tenant improvement costs, as well as other relevant market information, which are considered to be Level 3 inputs under the fair value measurements and disclosure guidance. The building and improvements have a weighted average useful life of 30 years. The fair value of the land was determined using comparable sales of land within the surrounding market, which is considered to be a Level 2 input. | ||||||||||||
During the last two years, we also completed a number of smaller acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition. | ||||||||||||
Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes. The pro forma results of operations for our business acquisitions and the results of operations for these acquisitions since the acquisition date have not been presented because the effects were not material to the consolidated financial statements on either an individual or an aggregate basis. | ||||||||||||
Celesio [Member] | ' | |||||||||||
Business Acquisition [Line Items] | ' | |||||||||||
Acquisition of Celesio AG | ' | |||||||||||
3 | Acquisition of Celesio AG | |||||||||||
On October 24, 2013, we entered into (i) a Share Purchase Agreement (the “SPA”) with Franz Haniel & Cie. GmbH (“Haniel”) and (ii) a Business Combination Agreement (the “BCA”) with Celesio AG (“Celesio”). Celesio’s issued and outstanding share capital was 50.01% owned by Haniel. Celesio is an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. Celesio operates in 14 countries and is headquartered in Stuttgart, Germany. | ||||||||||||
Under the original terms of the SPA and BCA, McKesson was to acquire a majority stake in Celesio for €23.00 per share from Haniel and launch a parallel voluntary public tender offer to purchase Celesio’s publicly-traded shares at €23.00 per share (the “Share Offer”) and tender offers for its outstanding convertible bonds at a price corresponding to the value of the underlying shares implied by a €23.00 per share offer price (the “Bond Offers” and, together with the “Share Offer,” the “2013 Tender Offers”). | ||||||||||||
The total original proposed transaction, including the assumption of Celesio’s outstanding debt, was valued at approximately €6.1 billion (or, assuming a currency exchange ratio of $1.35/1€, approximately $8.3 billion). The SPA included provisions allowing either party to terminate the agreement if certain conditions were not met. In particular, if applicable antitrust approval was not received by the closing date, or if we did not acquire at least 75% of Celesio’s shares on a fully diluted basis, either Haniel or McKesson could terminate the agreement. We intended to complete the acquisition by utilizing the below described senior bridge term loan and cash on hand. | ||||||||||||
In October 2013, we entered into a $5.5 billion 364-day unsecured Senior Bridge Term Loan Agreement (the “2013 Bridge Loan”). The 2013 Bridge Loan contained terms substantially similar to those contained in our existing revolving credit facility. Borrowings under the 2013 Bridge Loan were generally to bear interest based upon either a prime rate or the London Interbank Offered Rate. In addition, the 2013 Bridge Loan required that we maintain a debt to capital ratio of no greater than 65% throughout the term of the 2013 Bridge Loan. We expected to refinance all or part of the outstanding amounts under the 2013 Bridge Loan with longer-term financing prior to the end of the 2013 Bridge Loan’s 364-day term. | ||||||||||||
In October 2013, we also entered into a foreign currency option (the “Option”) to hedge a portion of the Euro denominated acquisition purchase price. The Option provided the right but not the obligation to purchase €1.6 billion at $1.40/1€. The Option was not designated for hedge accounting and, accordingly, changes in the fair value of the contract of $13 million were recorded directly in earnings for the quarter ended December 31, 2013. | ||||||||||||
In November 2013, we amended our Accounts Receivable Sales Facility and Revolving Credit Facility (these facilities are described in Financial Note 10, “Debt and Financing Activities”). The amendments added an extended cure period to both facilities with respect to defaults under the facilities relating to Celesio. Additionally, the amendments increased the maximum debt to capital ratio covenant from 56.5% to 65% for the Accounts Receivable Sales Facility, and upon completion of the acquisition of Celesio, for the Revolving Credit Facility. | ||||||||||||
On December 5, 2013, we commenced the voluntary public tender offers. On January 9, 2014, we and Haniel amended the SPA to increase the price to be paid per share of Celesio from €23.00 to €23.50 and we increased the purchase price in the Share Offer to €23.50 per share and the purchase price offered in the Bond Offers to a price corresponding to the value of the underlying shares implied by a €23.50 per share offer price. The Tender Offers expired on January 9, 2014. On January 13, 2014, the commitments under the 2013 Bridge Loan automatically terminated upon the failure of the 2013 Tender Offers and the provisions of the amendments to the Accounts Receivable Sales Facility and Revolving Credit Facility terminated other than the increase to the debt to capital ratio for the Accounts Receivable Sales Facility, which remains in effect. On January 13, 2014, we announced that the 2013 Tender Offers had failed to meet the minimum 75% completion condition outlined in the 2013 Tender Offers. On January 17, 2014, the Option expired. | ||||||||||||
On January 23, 2014, we entered into (i) an amendment to the BCA, (ii) an amended and restated SPA with Haniel, and (iii) a Bond Purchase Agreement with Elliott International, L.P., The Liverpool Limited Partnership and Elliott Capital Advisers, L.P. (collectively, the “Acquisition”). Upon completion of the Acquisition, we will acquire approximately 75.99% of Celesio’s shares currently outstanding for €23.50 per share. These agreements are not subject to any closing conditions. The Acquisition is expected to close during our fourth quarter of fiscal year 2014, which will result in McKesson achieving more than 75% ownership of Celesio shares on a fully diluted basis following a conversion of the Celesio convertible bonds into Celesio shares. We intend to utilize the below described bridge term loan and cash on hand to complete the Acquisition. We also intend to launch and complete a voluntary tender offer ( the “2014 Tender Offer”) of €23.50 per Celesio share in the fourth quarter of fiscal year 2014. The total proposed transaction, including the assumption of Celesio’s outstanding debt, is currently valued at approximately €6.4 billion (or, assuming a currency exchange ratio of $1.37/1€ as of January 23, 2014, approximately $8.7 billion). | ||||||||||||
On January 23, 2014, we entered into a $5.5 billion 364-day unsecured Senior Bridge Term Loan Agreement (the “2014 Bridge Loan”) under terms substantially similar to those previously in place for the 2013 Bridge Loan. The borrowings under the 2014 Bridge Loan will be made available to us at our request to: (i) pay the Acquisition consideration, (ii) fund additional acquisitions, if any, of Celesio shares and convertible bonds, including shares acquired in the 2014 Tender Offer and (iii) pay transaction costs associated with the Acquisition. The 2014 Bridge Loan requires that we maintain a debt to capital ratio of no greater than 65% throughout the term of the 2014 Bridge Loan. In the fourth quarter of fiscal year 2014, we amended our Accounts Receivable Sales Facility and Revolving Credit Facility to revive the extended cure period under both facilities with respect to defaults relating to Celesio and to the Revolving Credit Facility to revive the change of the debt to capital ratio from 56.5% to 65%. We expect that we will refinance all or part of the outstanding amounts under the 2014 Bridge Loan with longer-term financing prior to the end of the 2014 Bridge Loan’s 364-day term. | ||||||||||||
During the quarter ended December 31, 2013, we incurred $35 million of expenses related to the acquisition of Celesio. These expenses primarily consisted of professional fees, Option costs and fees associated with the 2013 Bridge Loan. Amounts incurred prior to the third quarter were not material. Expenses were recorded within the Corporate segment as follows: $12 million in operating expenses, $13 million in other income (loss), net and $10 million in interest expense in our condensed consolidated statement of operations. |
Technology_Solutions_Charges_N
Technology Solutions Charges (Notes) | 9 Months Ended | |
Dec. 31, 2013 | ||
Reorganization and Integration-related Expenses [Abstract] | ' | |
Technology Solutions Charges | ' | |
4 | Technology Solutions Charges | |
During the third quarter of 2014, our Technology Solutions segment recorded pre-tax charges totaling $57 million. These charges primarily consist of $35 million of product alignment charges, $15 million of integration-related expenses and $7 million of reduction-in-workforce severance charges. Included in the total charge was $35 million for severance for employees primarily in our research and development, customer services and sales functions, and $15 million for asset impairments which primarily represents the write-off of deferred costs related to a product that will no longer be developed. Charges were recorded in our condensed consolidated statement of operations as follows: $34 million in cost of sales and $23 million in operating expenses. |
Sale_of_an_Equity_Investment
Sale of an Equity Investment | 9 Months Ended |
Dec. 31, 2013 | |
Equity Method Investments and Joint Ventures [Abstract] | ' |
Sale of an equity investment [Text Block] | ' |
Sale of an Equity Investment | |
In September 2013, we completed the sale of our 49% equity interest in Nadro, S.A. de C.V. (“Nadro”). Under the terms of the agreement, we received $41 million in total cash consideration. There was no material gain or loss on the disposition based on the adjusted net realizable value of the investment at the time of the sale. Prior to the sale, our investment in Nadro was accounted for under the equity method of accounting within our Distribution Solutions segment. |
Income_Taxes
Income Taxes | 9 Months Ended |
Dec. 31, 2013 | |
Income Tax Disclosure [Abstract] | ' |
Income taxes | ' |
Income Taxes | |
As of December 31, 2013, we had $656 million of unrecognized tax benefits, of which $500 million would reduce income tax expense and the effective tax rate, if recognized. During the next twelve months, it is reasonably possible that audit resolutions and the expiration of statutes of limitations could potentially reduce our unrecognized tax benefits by up to $227 million. However, this amount may change because we continue to have ongoing negotiations with various taxing authorities throughout the year. | |
We have received reassessments from the Canada Revenue Agency (“CRA”) for a total of $210 million related to a transfer pricing matter impacting years 2003 through 2008. Payments of approximately $156 million of these reassessments have been made to the CRA to stop the accrual of interest. In prior years, we appealed the reassessment for 2003 to the Tax Court of Canada and filed a notice of objection for 2004 through 2008. On December 13, 2013, the Tax Court of Canada dismissed our appeal of the reassessment with respect to 2003. On January 10, 2014, we filed a Notice of Appeal to the Federal Court of Appeal from the judgment of the Tax Court of Canada. As a result of the unfavorable Tax Court Decision relating to 2003, we recognized a discrete tax charge of $122 million in the quarter, which includes tax and interest for the years 2003 through 2013. The ultimate resolution of these issues could result in an increase or decrease to income tax expense. | |
We have received tax assessments of $98 million from the U.S. Internal Revenue Service (“IRS”) relating to 2003 through 2006. We disagree with a substantial portion of the tax assessments primarily relating to transfer pricing. We are pursuing administrative relief through the appeals process. We continue to believe in the merits of our tax positions and that we have adequately provided for any potential adverse results relating to these examinations in our financial statements. | |
The IRS is currently examining our U.S. corporation income tax returns for 2007 through 2009. The CRA is currently examining our Canadian income tax returns for 2009 through 2013. In nearly all jurisdictions, the tax years prior to 2003 are no longer subject to examination. | |
We report interest and penalties on tax deficiencies as income tax expense. At December 31, 2013, before any tax benefits, our accrued interest and penalties on unrecognized tax benefits amounted to $180 million. We recognized an income tax expense of $44 million and $50 million, before any tax benefit, related to interest and penalties in our condensed consolidated statements of operations during the third quarter and first nine months of 2014. |
Discontinued_Operations
Discontinued Operations | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | ' | |||||||||||||||
Discontinued operations | ' | |||||||||||||||
Discontinued Operations | ||||||||||||||||
In the first quarter of 2014, we committed to a plan to sell our International Technology and our Hospital Automation businesses from our Technology Solutions segment and a small business from our Distribution Solutions segment. The results of operations and cash flows for these businesses are classified as discontinued operations for the quarter and nine months ended December 31, 2013 and 2012 in our condensed consolidated financial statements. | ||||||||||||||||
During the third quarter of 2014, we recorded an $80 million non-cash pre-tax and after-tax impairment charge to reduce the carrying value of our International Technology business to its estimated net realizable value (fair value less costs to sell). The charge is primarily the result of the terms of the preliminary purchase offers received for this business during the third quarter of 2014. The ultimate selling price of our International Technology business may be higher or lower than our current assessment of fair value. The impairment charge is included in loss from discontinued operations, net of tax, in our condensed consolidated statement of operations. The impairment charge was primarily attributed to goodwill and other long-lived assets of our International Technology business which are included in the assets classified as held for sale at December 31, 2013. There was no tax benefit associated with the impairment charge. | ||||||||||||||||
On October 31, 2013, we sold our Hospital Automation business for net cash proceeds of $55 million and recorded a pre-tax and after-tax loss of $5 million and $7 million. | ||||||||||||||||
A summary of results of discontinued operations is as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Revenues | $ | 78 | $ | 88 | $ | 304 | $ | 282 | ||||||||
Loss from discontinued operations | $ | (85 | ) | $ | (13 | ) | $ | (98 | ) | $ | (5 | ) | ||||
Loss on sale | (5 | ) | — | (5 | ) | — | ||||||||||
Loss from discontinued operations before income tax | (90 | ) | (13 | ) | (103 | ) | (5 | ) | ||||||||
Income tax (expense) benefit | (2 | ) | 5 | 3 | — | |||||||||||
Loss from discontinued operations, net of tax | $ | (92 | ) | $ | (8 | ) | $ | (100 | ) | $ | (5 | ) | ||||
The assets and liabilities of our discontinued operations were classified as held-for-sale effective June 30, 2013. All applicable assets of the businesses to be sold are included under the caption “Prepaid expenses and other” and all applicable liabilities under the caption “Other accrued liabilities” within our condensed consolidated balance sheet at December 31, 2013. The carrying values of the assets and liabilities classified as held-for-sale were $258 million and $207 million at December 31, 2013. |
Earnings_Per_Common_Share
Earnings Per Common Share | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Earnings Per Share [Abstract] | ' | |||||||||||||||
Earnings per common share | ' | |||||||||||||||
Earnings Per Common Share | ||||||||||||||||
Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. | ||||||||||||||||
The computations for basic and diluted earnings per common share are as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions, except per share amounts) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Income from continuing operations | $ | 156 | $ | 306 | $ | 992 | $ | 1,084 | ||||||||
Loss from discontinued operations, net of tax | (92 | ) | (8 | ) | (100 | ) | (5 | ) | ||||||||
Net income | $ | 64 | $ | 298 | $ | 892 | $ | 1,079 | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 230 | 235 | 229 | 236 | ||||||||||||
Effect of dilutive securities: | ||||||||||||||||
Options to purchase common stock | 2 | 1 | 1 | 1 | ||||||||||||
Restricted stock units | 2 | 4 | 3 | 3 | ||||||||||||
Diluted | 234 | 240 | 233 | 240 | ||||||||||||
Earnings (loss) per common share: (1) | ||||||||||||||||
Diluted | ||||||||||||||||
Continuing operations | $ | 0.67 | $ | 1.27 | $ | 4.26 | $ | 4.51 | ||||||||
Discontinued operations | (0.39 | ) | (0.03 | ) | (0.43 | ) | (0.02 | ) | ||||||||
Total | $ | 0.28 | $ | 1.24 | $ | 3.83 | $ | 4.49 | ||||||||
Basic | ||||||||||||||||
Continuing operations | $ | 0.68 | $ | 1.3 | $ | 4.34 | $ | 4.6 | ||||||||
Discontinued operations | (0.40 | ) | (0.03 | ) | (0.44 | ) | (0.02 | ) | ||||||||
Total | $ | 0.28 | $ | 1.27 | $ | 3.9 | $ | 4.58 | ||||||||
-1 | Certain computations may reflect rounding adjustments. | |||||||||||||||
Potentially dilutive securities include outstanding stock options, restricted stock units and performance-based restricted stock units. Approximately nil and 1 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for the quarters ended December 31, 2013 and 2012 and 3 million and 5 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for the nine months ended December 31, 2013 and 2012, as they were anti-dilutive. |
Goodwill_And_Intangible_Assets
Goodwill And Intangible Assets, Net | 9 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||||
Goodwill and intangible assets, net | ' | |||||||||||||||||||||||||
Goodwill and Intangible Assets, Net | ||||||||||||||||||||||||||
Changes in the carrying amount of goodwill were as follows: | ||||||||||||||||||||||||||
(In millions) | Distribution | Technology | Total | |||||||||||||||||||||||
Solutions | Solutions | |||||||||||||||||||||||||
Balance at March 31, 2013 | $ | 4,413 | $ | 1,992 | $ | 6,405 | ||||||||||||||||||||
Goodwill acquired | 45 | — | 45 | |||||||||||||||||||||||
Amount reclassified to assets held-for-sale | — | (127 | ) | (127 | ) | |||||||||||||||||||||
Foreign currency translation adjustments and other | (13 | ) | (10 | ) | (23 | ) | ||||||||||||||||||||
Balance at December 31, 2013 | $ | 4,445 | $ | 1,855 | $ | 6,300 | ||||||||||||||||||||
As of December 31, 2013 and March 31, 2013, the accumulated goodwill impairment losses were $36 million in our Technology Solutions segment. | ||||||||||||||||||||||||||
Information regarding intangible assets is as follows: | ||||||||||||||||||||||||||
December 31, 2013 | March 31, 2013 | |||||||||||||||||||||||||
(Dollars in millions) | Weighted | Gross | Accumulated | Net | Gross | Accumulated | Net | |||||||||||||||||||
Average | Carrying | Amortization | Carrying | Carrying | Amortization | Carrying | ||||||||||||||||||||
Remaining | Amount | Amount | Amount | Amount | ||||||||||||||||||||||
Amortization | ||||||||||||||||||||||||||
Period | ||||||||||||||||||||||||||
(years) | ||||||||||||||||||||||||||
Customer lists | 7 | $ | 1,791 | $ | (804 | ) | $ | 987 | $ | 1,761 | $ | (672 | ) | $ | 1,089 | |||||||||||
Service agreements | 17 | 999 | (157 | ) | 842 | 1,018 | (114 | ) | 904 | |||||||||||||||||
Trademarks and trade names | 16 | 201 | (53 | ) | 148 | 208 | (46 | ) | 162 | |||||||||||||||||
Technology | 4 | 215 | (170 | ) | 45 | 271 | (207 | ) | 64 | |||||||||||||||||
Other | 6 | 86 | (42 | ) | 44 | 89 | (38 | ) | 51 | |||||||||||||||||
Total | $ | 3,292 | $ | (1,226 | ) | $ | 2,066 | $ | 3,347 | $ | (1,077 | ) | $ | 2,270 | ||||||||||||
Amortization expense of intangible assets was $70 million and $211 million for the quarter and nine months ended December 31, 2013 and $52 million and $147 million for the quarter and nine months ended December 31, 2012. Estimated annual amortization expense of these assets is as follows: $279 million, $261 million, $229 million, $207 million and $190 million for 2014 through 2018 and $1,111 million thereafter. All intangible assets were subject to amortization as of December 31, 2013 and March 31, 2013. |
Debt_and_Financing_Activities
Debt and Financing Activities | 9 Months Ended |
Dec. 31, 2013 | |
Debt Disclosure [Abstract] | ' |
Debt and Financing Activities | ' |
Debt and Financing Activities | |
Accounts Receivable Sales Facility | |
In May 2013, we extended our existing accounts receivable sales facility for a six month period under terms substantially similar to those previously in place. In November 2013, we amended the facility to extend the term for an additional year, increased the maximum debt to capital ratio from 56.5% to 65% and added an extended cure period with respect to defaults under the facility relating to Celesio. The committed balance of the facility is $1.35 billion, although from time-to-time, the available amount of the facility may be less than $1.35 billion based on accounts receivable concentration limits and other eligibility requirements. On January 13, 2014, the amendment to the extended cure period terminated upon the failure of the 2013 Tender Offers. The increase to the debt to capital ratio remains in effect. In the fourth quarter of fiscal 2014, we amended this facility to revive the extended cure period with respect to defaults relating to Celesio. The amended facility will expire in November 2014. We anticipate renewing the facility before expiration. | |
During the first nine months of 2014, we borrowed and repaid $150 million of short-term borrowings under the facility; and for the first nine months of 2013, we borrowed and repaid $1,125 million and $1,525 million. At December 31, 2013 and March 31, 2013, there were no short-term borrowings and related securitized accounts receivable outstanding under this facility. | |
The facility contains requirements relating to the performance of the accounts receivable and covenants relating to the Company. If we do not comply with these covenants, our ability to use the facility may be suspended and repayments of any outstanding balances under the facility may be required. At December 31, 2013 and March 31, 2013, we were in compliance with all covenants. | |
Revolving Credit Facility | |
We have a syndicated $1.3 billion five-year senior unsecured revolving credit facility, which expires in September 2016. In November 2013, we amended this facility to increase the maximum debt to capital ratio from 56.5% to 65%, effective upon the Celesio acquisition date, and added an extended cure period with respect to defaults under the credit facility relating to Celesio. On January 13, 2014, the amendment to the Revolving Credit Facility terminated upon the failure of the 2013 Tender Offers. The maximum debt to capital ratio on this facility remained at 56.5% as of December 31, 2013. Borrowings under this facility bear interest based upon either the London Interbank Offered Rate or a prime rate. There were no borrowings under this facility during the first nine months of 2014 and 2013 and as of December 31, 2013 and March 31, 2013, there were no amounts outstanding under this facility. In the fourth quarter of fiscal 2014, we amended this facility to revive the extended cure period with respect to defaults relating to Celesio and the change of the debt to capital ratio from 56.5% to 65%. | |
Refer to Financial Note 3, “Acquisition of Celesio AG”, for additional information regarding our financing activities. |
Hedging_Activities
Hedging Activities | 9 Months Ended |
Dec. 31, 2013 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' |
Hedging Activities | ' |
Hedging Activities | |
In the first quarter of 2013, we settled a forward contract to hedge British pound denominated cash flows with a gross notional value of $151 million. In the third quarter of 2013, we entered into an additional forward contract to hedge a separately identifiable Canadian dollar denominated cash flow with a notional value of $177 million. This contract was renewed and was settled on its maturity in the first quarter of 2014. In the second quarter of 2014, we entered into and settled a forward contract to hedge Mexican peso denominated cash flows related to our sale of Nadro with a gross notional value of $41 million. In the third quarter of 2014, we entered into a forward contract to hedge a separately identifiable Canadian dollar denominated cash flow with a notional value of $90 million. This contract matures in the fourth quarter of 2014. None of these contracts were designated for hedge accounting and, accordingly, changes in the fair values of these contracts were recorded directly in earnings. Amounts recorded to earnings were not material for the quarters and nine months ended December 31, 2013 and 2012. At December 31, 2013 and March 31, 2013, the gross notional values of the these contracts were $90 million and $172 million. | |
In 2012, we entered into a number of forward contracts to hedge Canadian dollar denominated cash flows. These contracts mature over a period of eight years, ending in 2020, and have been designated for hedge accounting. Accordingly, changes in the fair values of these contracts are recorded to accumulated other comprehensive income and reclassified into earnings in the same period in which the hedged transaction affects earnings. At December 31, 2013 and March 31, 2013, the gross notional values of these contracts, designated for hedge accounting, were $503 million. No amounts were reclassified to earnings in the quarters and nine months ended December 31, 2013 and 2012. | |
Refer to Financial Note 3, “Acquisition of Celesio AG,” for additional information regarding our hedging activities. |
Fair_Value_Measurements
Fair Value Measurements | 9 Months Ended |
Dec. 31, 2013 | |
Fair Value Disclosures [Abstract] | ' |
Fair Value Measurements | ' |
Fair Value Measurements | |
Assets Measured at Fair Value on a Recurring Basis | |
At December 31, 2013 and March 31, 2013, the carrying amounts of cash, cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable and other current liabilities generally approximated their estimated fair values because of the short maturity of these financial instruments. | |
Our long-term debt and other financing are carried at amortized cost. The carrying amounts and estimated fair values of these liabilities were $4.9 billion and $5.1 billion at December 31, 2013 and $4.9 billion and $5.5 billion at March 31, 2013. The estimated fair values of our long-term debt and other financing were determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future. | |
Cash and cash equivalents at December 31, 2013 and March 31, 2013 included investments in money market funds, time deposits and repurchase agreements of $2.0 billion and $1.6 billion, which are reported at fair value. The fair value of these investments was determined by using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature. | |
Fair values of our foreign currency derivatives were determined using quoted market prices of similar instruments in an active market and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. The fair value of these derivative contracts, which are subject to a master netting arrangement under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheet. Fair values for our foreign currency hedges were not material at December 31, 2013 and March 31, 2013. | |
There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the quarters and nine months ended December 31, 2013 and 2012. | |
Assets Measured at Fair Value on a Non-Recurring Basis | |
During the third quarter of 2014, we recorded an $80 million non-cash pre-tax and after-tax impairment charge to reduce the carrying value of our International Technology business to its estimated fair value, less costs to sell. The impairment charge was primarily the result of the terms of the preliminary purchase offers received for this business during the third quarter of 2014. Accordingly, the fair value measurement is classified as Level 3 in the fair value hierarchy. |
Commitments_and_Contingent_Lia
Commitments and Contingent Liabilities | 9 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Commitments and Contingencies Disclosure [Abstract] | ' | |||||||
Commitments and Contingent Liabilities | ' | |||||||
Commitments and Contingent Liabilities | ||||||||
In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, other pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. As described below, many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages. | ||||||||
When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided. | ||||||||
Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates. | ||||||||
Significant developments in previously reported proceedings and in other litigation and claims, since the filing of our 2013 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the periods ended June 30, 2013 and September 30, 2013, are set out below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations. | ||||||||
I. Litigation, Subpoenas and Investigations | ||||||||
From time-to-time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements. Examples of such requests and investigations are included in the Company's 2013 Annual Report on Form 10-K, and as previously reported, include subpoenas from the U.S. Drug Enforcement Agency to certain of the Company's pharmaceutical distribution facilities seeking information and records about the Company's distribution of certain controlled substances. The Company is currently responding to these requests. In addition, in the third quarter of 2014, the Company was informed of an investigation by the United States Department of Justice through the United States Attorney’s Office for the Northern District of West Virginia of potential claims under the Comprehensive Drug Abuse Prevention and Control Act. The Company believes that the investigation is focused on the Company’s pharmaceutical distribution of certain controlled substances by its Landover, Maryland distribution center, which closed in 2012. | ||||||||
II. Average Wholesale Price (“AWP”) Litigation | ||||||||
The Company has a reserve relating to AWP public entity claims, which is reviewed at least quarterly and whenever events or circumstances indicate changes, including consideration of the pace and progress of discussions relating to potentially resolving other public entity claims. Following our most recent review of the reserve for estimated probable losses from current and possible future public entity AWP claims, the Company recorded pre-tax charges of $15 million, $35 million and $18 million (total of $68 million) during the first, second and third quarters of 2014. The Company recorded pre-tax charges of $16 million and $44 million (total of $60 million) during the first and second quarters of 2013. No additional amounts were recorded in the third quarter of 2013. Pre-tax charges relating to changes in the Company’s AWP litigation reserve, including accrued interest, are recorded in our Distribution Solutions segment. The Company’s AWP litigation reserve is included in other current liabilities in the consolidated balance sheets. In view of the uncertainties of the timing and outcome of this type of litigation, it is possible that the ultimate costs of these matters may exceed or be less than the reserve. | ||||||||
The following is the activity related to the AWP litigation reserve for the first nine months of 2014 and 2013: | ||||||||
Nine Months Ended December 31, | ||||||||
(In millions) | 2013 | 2012 | ||||||
AWP litigation reserve at beginning of period | $ | 42 | $ | 453 | ||||
Charges incurred | 68 | 60 | ||||||
Payments made | (86 | ) | (470 | ) | ||||
AWP litigation reserve at end of period | $ | 24 | $ | 43 | ||||
Stockholders_Equity
Stockholders' Equity | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||||
Stockholders' Equity | ' | |||||||||||||||
Stockholders’ Equity | ||||||||||||||||
Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company’s Board of Directors (the “Board”). | ||||||||||||||||
In July 2013, the Company’s quarterly dividend was raised from $0.20 to $0.24 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors. | ||||||||||||||||
In the fourth quarter of 2013, we entered into an accelerated share repurchase program with a third party financial institution to repurchase $150 million of the Company’s common stock. As of March 31, 2013, we had received 1.2 million shares representing the minimum number of shares due under this program. This program was completed on April 17, 2013 and we received 0.2 million additional shares on April 22, 2013. The total number of shares repurchased under this program was 1.4 million shares at an average price per share of $107.63. | ||||||||||||||||
The total authorization outstanding for repurchases of the Company’s common stock was $340 million at December 31, 2013. | ||||||||||||||||
Other Comprehensive Income | ||||||||||||||||
Information regarding other comprehensive income, net of tax, by component are as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Foreign currency translation adjustments | ||||||||||||||||
Foreign currency translation adjustments arising during period, net of income tax (benefit) of nil, ($4), nil and ($2) | $ | (55 | ) | $ | (16 | ) | $ | (60 | ) | $ | 14 | |||||
Reclassified to income statement, net of income tax expense of nil, nil, $24 and nil (1) | — | — | 44 | — | ||||||||||||
(55 | ) | (16 | ) | (16 | ) | 14 | ||||||||||
Unrealized gains (losses) on cash flow hedges and other | ||||||||||||||||
Unrealized gains (losses) on cash flow hedges and other arising during period, net of income tax expense of nil, nil, nil and nil | (1 | ) | — | (2 | ) | 2 | ||||||||||
Changes in retirement-related benefit plans | ||||||||||||||||
Amortization of actuarial loss, prior service cost and transition obligation, net of income tax expense of $4, $3, $10 and $8 (2) | 3 | 5 | 16 | 14 | ||||||||||||
Foreign currency translation adjustments, net of income tax expense of nil, nil, nil and nil | 1 | — | (2 | ) | — | |||||||||||
Reclassified to income statement, net of income tax expense of nil, nil, $1 and nil | — | — | 1 | — | ||||||||||||
4 | 5 | 15 | 14 | |||||||||||||
Other Comprehensive Income (Loss), net of tax | $ | (52 | ) | $ | (11 | ) | $ | (3 | ) | $ | 30 | |||||
-1 | As a result of our sale of our 49% equity interest in Nadro, foreign currency translation net losses of $44 million were reclassified from AOCI to other income, within our condensed consolidated statement of operations. Such losses were previously considered in our impairment evaluation of the investment when we committed to a plan to sell the investment during the fourth quarter of 2013, and accordingly did not impact the 2014 earnings period for the third quarter and first nine months of 2014. | |||||||||||||||
-2 | Pre-tax amount was reclassified into cost of sales and operating expenses in the condensed consolidated statements of operations. The related tax expense (benefit) was reclassified into income tax expense in the condensed consolidated statements of operations. | |||||||||||||||
Accumulated Other Comprehensive Income (Loss) | ||||||||||||||||
Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component are as follows: | ||||||||||||||||
(In millions) | Foreign | Unrealized | Unrealized Net | Total | ||||||||||||
Currency | Losses on Cash | Loss and Other | Accumulated | |||||||||||||
Translation | Flow Hedges and Other, | Components of | Other | |||||||||||||
Adjustments, | Net of Tax | Benefit Plans, | Comprehensive | |||||||||||||
Net of Tax | Net of Tax | Income (Loss) | ||||||||||||||
Balance at March 31, 2013 | $ | 136 | $ | (5 | ) | $ | (196 | ) | $ | (65 | ) | |||||
Other comprehensive income (loss) before reclassifications | (60 | ) | (2 | ) | 14 | (48 | ) | |||||||||
Amounts reclassified to earnings | 44 | — | 1 | 45 | ||||||||||||
Other comprehensive income (loss) | (16 | ) | (2 | ) | 15 | (3 | ) | |||||||||
Balance at December 31, 2013 | $ | 120 | $ | (7 | ) | $ | (181 | ) | $ | (68 | ) | |||||
Segment_Information
Segment Information | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||
Segment Information | ' | |||||||||||||||
Segment Information | ||||||||||||||||
We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations. | ||||||||||||||||
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Revenues | ||||||||||||||||
Distribution Solutions (1) | ||||||||||||||||
Direct distribution & services | $ | 24,859 | $ | 22,386 | $ | 71,620 | $ | 64,625 | ||||||||
Sales to customers’ warehouses | 4,416 | 4,468 | 13,204 | 14,621 | ||||||||||||
Total U.S. pharmaceutical distribution & services | 29,275 | 26,854 | 84,824 | 79,246 | ||||||||||||
Canada pharmaceutical distribution & services | 2,785 | 2,633 | 7,984 | 7,559 | ||||||||||||
Medical-Surgical distribution & services | 1,462 | 874 | 4,286 | 2,542 | ||||||||||||
Total Distribution Solutions | 33,522 | 30,361 | 97,094 | 89,347 | ||||||||||||
Technology Solutions | ||||||||||||||||
Services | 658 | 598 | 1,975 | 1,777 | ||||||||||||
Software | 107 | 120 | 338 | 357 | ||||||||||||
Hardware | 19 | 20 | 61 | 72 | ||||||||||||
Total Technology Solutions | 784 | 738 | 2,374 | 2,206 | ||||||||||||
Total Revenues | $ | 34,306 | $ | 31,099 | $ | 99,468 | $ | 91,553 | ||||||||
Operating profit | ||||||||||||||||
Distribution Solutions (2) (3) (4) (5) | $ | 552 | $ | 525 | $ | 1,856 | $ | 1,646 | ||||||||
Technology Solutions (6) | 37 | 92 | 269 | 274 | ||||||||||||
Total | 589 | 617 | 2,125 | 1,920 | ||||||||||||
Corporate Expenses, Net (7) | (112 | ) | (109 | ) | (307 | ) | (212 | ) | ||||||||
Interest Expense | (69 | ) | (59 | ) | (187 | ) | (170 | ) | ||||||||
Income Before Income Taxes from Continuing Operations | $ | 408 | $ | 449 | $ | 1,631 | $ | 1,538 | ||||||||
-1 | Revenues derived from services represent less than 2% of this segment’s total revenues. | |||||||||||||||
-2 | Operating profit for the third quarter of 2014 includes AWP litigation charges of $18 million and for the first nine months of 2014 and 2013 includes AWP litigation charges of $68 million and $60 million, which were recorded in operating expenses. | |||||||||||||||
-3 | Operating profit for the third quarter and first nine months of 2014 includes last-in-first-out (“LIFO”) charges of $142 million and $186 million and, for the third quarter and first nine months of 2013 includes LIFO charges of $2 million and $5 million, which were recorded in cost of sales. | |||||||||||||||
-4 | Operating profit for the third quarter and first nine months of 2014 includes the receipt of $27 million and $34 million and for the third quarter and first nine months of fiscal year 2013 the receipt of $8 million and $27 million representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers, which was recorded as a reduction to cost of sales. | |||||||||||||||
-5 | Operating profit for the third quarter and first nine months of 2013 includes a $40 million charge for a legal dispute in our Canadian business, which was recorded in operating expenses. | |||||||||||||||
-6 | Technology Solutions segment results for the third quarter of 2014 include product alignment charges, integration-related expenses and reduction-in-workforce severance charges totaling $57 million, of which $34 million was recorded in cost of sales and $23 million was recorded in operating expenses. This segment’s results for the first nine months of 2014 include product alignment charges, integration-related expenses and reduction-in-workforce severance charges totaling $60 million, of which $34 million was recorded in cost of sales and $26 million was recorded in operating expenses. | |||||||||||||||
-7 | Corporate expenses, net for the third quarter and first nine months of 2014 include $25 million of acquisition-related expenses and for the first nine months of 2013 are net of an $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building. |
Significant_Accounting_Policie1
Significant Accounting Policies (Policy) | 9 Months Ended |
Dec. 31, 2013 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation | ' |
Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. We also evaluate our ownership, contractual and other interests in entities to determine if they are variable interest entities (“VIEs”), if we have a variable interest in those entities and the nature and extent of those interests. These evaluations are highly complex and involve judgment and the use of estimates and assumptions based on available historical information and management’s judgment, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. The consolidated VIEs are not material to our condensed consolidated financial statements. Intercompany transactions and balances have been eliminated. The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. | |
Use Of Estimates | ' |
To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented. | |
Reclassifications | ' |
Certain prior period amounts, which primarily relate to discontinued operations, have been reclassified to conform to the current period presentation. Refer to Financial Note 7, “Discontinued Operations,” for more information. | |
Fiscal Period | ' |
The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year. | |
Recently Adopted Accounting Pronouncements | ' |
Balance Sheet Offsetting: In the first quarter of 2014, we adopted disclosure guidance on a retrospective basis related to the offsetting of assets and liabilities. The guidance requires an entity to disclose information about offsetting assets and liabilities for derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific GAAP criteria or subject to a master netting arrangement or similar agreement. The adoption of this guidance did not have a material effect on our condensed consolidated financial statements. | |
Comprehensive Income: In the first quarter of 2014, we adopted disclosure guidance on a prospective basis related to the reporting of amounts reclassified out of Accumulated Other Comprehensive Income ("AOCI”). The guidance requires disclosure of amounts reclassified out of AOCI by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. The adoption of this guidance did not have a material effect on our condensed consolidated financial statements. | |
Recently Issued Accounting Pronouncements Not Yet Adopted | ' |
Cumulative Translation Adjustments: In March 2013, amended guidance was issued for a parent’s accounting for the cumulative translation adjustment upon derecognition of certain subsidiaries or group of assets within a foreign entity or of an investment in a foreign entity. The amended guidance requires the release of any cumulative translation adjustment into net income only upon complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity. Also, it requires the release of all or a pro rata portion of the cumulative translation adjustment to net income in case of sale of an equity method investment that is a foreign entity. The amended guidance is applicable to us effective in the first quarter of fiscal 2015. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements. |
Business_Combinations_Tables
Business Combinations (Tables) (PSS World Medical [Member]) | 9 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
PSS World Medical [Member] | ' | |||||||||||
Business Acquisition [Line Items] | ' | |||||||||||
Fair value of assets acquired and liabilities assumed | ' | |||||||||||
The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date: | ||||||||||||
(In millions) | Amounts | Measurement | Amounts | |||||||||
Previously | Period | Recognized as of | ||||||||||
Recognized as of | Adjustments | Acquisition Date | ||||||||||
Acquisition Date | (Provisional as | |||||||||||
(Provisional)(1) | Adjusted) | |||||||||||
Current assets, net of cash and cash equivalents acquired | $ | 706 | $ | 5 | $ | 711 | ||||||
Goodwill | 1,145 | (15 | ) | 1,130 | ||||||||
Intangible assets | 557 | 11 | 568 | |||||||||
Other long-term assets | 183 | (1 | ) | 182 | ||||||||
Current liabilities | (376 | ) | 3 | (373 | ) | |||||||
Current portion of long-term debt | (635 | ) | — | (635 | ) | |||||||
Other long-term liabilities | (281 | ) | (3 | ) | (284 | ) | ||||||
Net assets acquired, less cash and cash equivalents | $ | 1,299 | $ | — | $ | 1,299 | ||||||
-1 | As previously reported in our Form 10-K for the year ended March 31, 2013. |
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | ' | |||||||||||||||
Schedule of Results from Discontinued Operations | ' | |||||||||||||||
A summary of results of discontinued operations is as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Revenues | $ | 78 | $ | 88 | $ | 304 | $ | 282 | ||||||||
Loss from discontinued operations | $ | (85 | ) | $ | (13 | ) | $ | (98 | ) | $ | (5 | ) | ||||
Loss on sale | (5 | ) | — | (5 | ) | — | ||||||||||
Loss from discontinued operations before income tax | (90 | ) | (13 | ) | (103 | ) | (5 | ) | ||||||||
Income tax (expense) benefit | (2 | ) | 5 | 3 | — | |||||||||||
Loss from discontinued operations, net of tax | $ | (92 | ) | $ | (8 | ) | $ | (100 | ) | $ | (5 | ) |
Earnings_Per_Common_Share_Tabl
Earnings Per Common Share (Tables) | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Earnings Per Share [Abstract] | ' | |||||||||||||||
Basic And Diluted Earnings Per Common Share | ' | |||||||||||||||
The computations for basic and diluted earnings per common share are as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions, except per share amounts) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Income from continuing operations | $ | 156 | $ | 306 | $ | 992 | $ | 1,084 | ||||||||
Loss from discontinued operations, net of tax | (92 | ) | (8 | ) | (100 | ) | (5 | ) | ||||||||
Net income | $ | 64 | $ | 298 | $ | 892 | $ | 1,079 | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 230 | 235 | 229 | 236 | ||||||||||||
Effect of dilutive securities: | ||||||||||||||||
Options to purchase common stock | 2 | 1 | 1 | 1 | ||||||||||||
Restricted stock units | 2 | 4 | 3 | 3 | ||||||||||||
Diluted | 234 | 240 | 233 | 240 | ||||||||||||
Earnings (loss) per common share: (1) | ||||||||||||||||
Diluted | ||||||||||||||||
Continuing operations | $ | 0.67 | $ | 1.27 | $ | 4.26 | $ | 4.51 | ||||||||
Discontinued operations | (0.39 | ) | (0.03 | ) | (0.43 | ) | (0.02 | ) | ||||||||
Total | $ | 0.28 | $ | 1.24 | $ | 3.83 | $ | 4.49 | ||||||||
Basic | ||||||||||||||||
Continuing operations | $ | 0.68 | $ | 1.3 | $ | 4.34 | $ | 4.6 | ||||||||
Discontinued operations | (0.40 | ) | (0.03 | ) | (0.44 | ) | (0.02 | ) | ||||||||
Total | $ | 0.28 | $ | 1.27 | $ | 3.9 | $ | 4.58 | ||||||||
-1 | Certain computations may reflect rounding adjustments. |
Goodwill_And_Intangible_Assets1
Goodwill And Intangible Assets, Net (Tables) | 9 Months Ended | |||||||||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||||
Changes In The Carrying Amount Of Goodwill | ' | |||||||||||||||||||||||||
Changes in the carrying amount of goodwill were as follows: | ||||||||||||||||||||||||||
(In millions) | Distribution | Technology | Total | |||||||||||||||||||||||
Solutions | Solutions | |||||||||||||||||||||||||
Balance at March 31, 2013 | $ | 4,413 | $ | 1,992 | $ | 6,405 | ||||||||||||||||||||
Goodwill acquired | 45 | — | 45 | |||||||||||||||||||||||
Amount reclassified to assets held-for-sale | — | (127 | ) | (127 | ) | |||||||||||||||||||||
Foreign currency translation adjustments and other | (13 | ) | (10 | ) | (23 | ) | ||||||||||||||||||||
Balance at December 31, 2013 | $ | 4,445 | $ | 1,855 | $ | 6,300 | ||||||||||||||||||||
Information Regarding Intangible Assets | ' | |||||||||||||||||||||||||
Information regarding intangible assets is as follows: | ||||||||||||||||||||||||||
December 31, 2013 | March 31, 2013 | |||||||||||||||||||||||||
(Dollars in millions) | Weighted | Gross | Accumulated | Net | Gross | Accumulated | Net | |||||||||||||||||||
Average | Carrying | Amortization | Carrying | Carrying | Amortization | Carrying | ||||||||||||||||||||
Remaining | Amount | Amount | Amount | Amount | ||||||||||||||||||||||
Amortization | ||||||||||||||||||||||||||
Period | ||||||||||||||||||||||||||
(years) | ||||||||||||||||||||||||||
Customer lists | 7 | $ | 1,791 | $ | (804 | ) | $ | 987 | $ | 1,761 | $ | (672 | ) | $ | 1,089 | |||||||||||
Service agreements | 17 | 999 | (157 | ) | 842 | 1,018 | (114 | ) | 904 | |||||||||||||||||
Trademarks and trade names | 16 | 201 | (53 | ) | 148 | 208 | (46 | ) | 162 | |||||||||||||||||
Technology | 4 | 215 | (170 | ) | 45 | 271 | (207 | ) | 64 | |||||||||||||||||
Other | 6 | 86 | (42 | ) | 44 | 89 | (38 | ) | 51 | |||||||||||||||||
Total | $ | 3,292 | $ | (1,226 | ) | $ | 2,066 | $ | 3,347 | $ | (1,077 | ) | $ | 2,270 | ||||||||||||
Commitments_and_Contingent_Lia1
Commitments and Contingent Liabilities (Tables) (Average Wholesale Price Litigation [Member]) | 9 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Average Wholesale Price Litigation [Member] | ' | |||||||
Loss Contingencies [Line Items] | ' | |||||||
Litigation Reserve and Expense | ' | |||||||
The following is the activity related to the AWP litigation reserve for the first nine months of 2014 and 2013: | ||||||||
Nine Months Ended December 31, | ||||||||
(In millions) | 2013 | 2012 | ||||||
AWP litigation reserve at beginning of period | $ | 42 | $ | 453 | ||||
Charges incurred | 68 | 60 | ||||||
Payments made | (86 | ) | (470 | ) | ||||
AWP litigation reserve at end of period | $ | 24 | $ | 43 | ||||
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Stockholders' Equity Attributable to Parent [Abstract] | ' | |||||||||||||||
Schedule of Comprehensive Income (Loss) | ' | |||||||||||||||
Information regarding other comprehensive income, net of tax, by component are as follows: | ||||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Foreign currency translation adjustments | ||||||||||||||||
Foreign currency translation adjustments arising during period, net of income tax (benefit) of nil, ($4), nil and ($2) | $ | (55 | ) | $ | (16 | ) | $ | (60 | ) | $ | 14 | |||||
Reclassified to income statement, net of income tax expense of nil, nil, $24 and nil (1) | — | — | 44 | — | ||||||||||||
(55 | ) | (16 | ) | (16 | ) | 14 | ||||||||||
Unrealized gains (losses) on cash flow hedges and other | ||||||||||||||||
Unrealized gains (losses) on cash flow hedges and other arising during period, net of income tax expense of nil, nil, nil and nil | (1 | ) | — | (2 | ) | 2 | ||||||||||
Changes in retirement-related benefit plans | ||||||||||||||||
Amortization of actuarial loss, prior service cost and transition obligation, net of income tax expense of $4, $3, $10 and $8 (2) | 3 | 5 | 16 | 14 | ||||||||||||
Foreign currency translation adjustments, net of income tax expense of nil, nil, nil and nil | 1 | — | (2 | ) | — | |||||||||||
Reclassified to income statement, net of income tax expense of nil, nil, $1 and nil | — | — | 1 | — | ||||||||||||
4 | 5 | 15 | 14 | |||||||||||||
Other Comprehensive Income (Loss), net of tax | $ | (52 | ) | $ | (11 | ) | $ | (3 | ) | $ | 30 | |||||
-1 | As a result of our sale of our 49% equity interest in Nadro, foreign currency translation net losses of $44 million were reclassified from AOCI to other income, within our condensed consolidated statement of operations. Such losses were previously considered in our impairment evaluation of the investment when we committed to a plan to sell the investment during the fourth quarter of 2013, and accordingly did not impact the 2014 earnings period for the third quarter and first nine months of 2014. | |||||||||||||||
-2 | Pre-tax amount was reclassified into cost of sales and operating expenses in the condensed consolidated statements of operations. The related tax expense (benefit) was reclassified into income tax expense in the condensed consolidated statements of operations. | |||||||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) | ' | |||||||||||||||
Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component are as follows: | ||||||||||||||||
(In millions) | Foreign | Unrealized | Unrealized Net | Total | ||||||||||||
Currency | Losses on Cash | Loss and Other | Accumulated | |||||||||||||
Translation | Flow Hedges and Other, | Components of | Other | |||||||||||||
Adjustments, | Net of Tax | Benefit Plans, | Comprehensive | |||||||||||||
Net of Tax | Net of Tax | Income (Loss) | ||||||||||||||
Balance at March 31, 2013 | $ | 136 | $ | (5 | ) | $ | (196 | ) | $ | (65 | ) | |||||
Other comprehensive income (loss) before reclassifications | (60 | ) | (2 | ) | 14 | (48 | ) | |||||||||
Amounts reclassified to earnings | 44 | — | 1 | 45 | ||||||||||||
Other comprehensive income (loss) | (16 | ) | (2 | ) | 15 | (3 | ) | |||||||||
Balance at December 31, 2013 | $ | 120 | $ | (7 | ) | $ | (181 | ) | $ | (68 | ) | |||||
Segment_Information_Tables
Segment Information (Tables) | 9 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||
Schedule of Segment Reporting Information, by Segment | ' | |||||||||||||||
Quarter Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
(In millions) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Revenues | ||||||||||||||||
Distribution Solutions (1) | ||||||||||||||||
Direct distribution & services | $ | 24,859 | $ | 22,386 | $ | 71,620 | $ | 64,625 | ||||||||
Sales to customers’ warehouses | 4,416 | 4,468 | 13,204 | 14,621 | ||||||||||||
Total U.S. pharmaceutical distribution & services | 29,275 | 26,854 | 84,824 | 79,246 | ||||||||||||
Canada pharmaceutical distribution & services | 2,785 | 2,633 | 7,984 | 7,559 | ||||||||||||
Medical-Surgical distribution & services | 1,462 | 874 | 4,286 | 2,542 | ||||||||||||
Total Distribution Solutions | 33,522 | 30,361 | 97,094 | 89,347 | ||||||||||||
Technology Solutions | ||||||||||||||||
Services | 658 | 598 | 1,975 | 1,777 | ||||||||||||
Software | 107 | 120 | 338 | 357 | ||||||||||||
Hardware | 19 | 20 | 61 | 72 | ||||||||||||
Total Technology Solutions | 784 | 738 | 2,374 | 2,206 | ||||||||||||
Total Revenues | $ | 34,306 | $ | 31,099 | $ | 99,468 | $ | 91,553 | ||||||||
Operating profit | ||||||||||||||||
Distribution Solutions (2) (3) (4) (5) | $ | 552 | $ | 525 | $ | 1,856 | $ | 1,646 | ||||||||
Technology Solutions (6) | 37 | 92 | 269 | 274 | ||||||||||||
Total | 589 | 617 | 2,125 | 1,920 | ||||||||||||
Corporate Expenses, Net (7) | (112 | ) | (109 | ) | (307 | ) | (212 | ) | ||||||||
Interest Expense | (69 | ) | (59 | ) | (187 | ) | (170 | ) | ||||||||
Income Before Income Taxes from Continuing Operations | $ | 408 | $ | 449 | $ | 1,631 | $ | 1,538 | ||||||||
-1 | Revenues derived from services represent less than 2% of this segment’s total revenues. | |||||||||||||||
-2 | Operating profit for the third quarter of 2014 includes AWP litigation charges of $18 million and for the first nine months of 2014 and 2013 includes AWP litigation charges of $68 million and $60 million, which were recorded in operating expenses. | |||||||||||||||
-3 | Operating profit for the third quarter and first nine months of 2014 includes last-in-first-out (“LIFO”) charges of $142 million and $186 million and, for the third quarter and first nine months of 2013 includes LIFO charges of $2 million and $5 million, which were recorded in cost of sales. | |||||||||||||||
-4 | Operating profit for the third quarter and first nine months of 2014 includes the receipt of $27 million and $34 million and for the third quarter and first nine months of fiscal year 2013 the receipt of $8 million and $27 million representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers, which was recorded as a reduction to cost of sales. | |||||||||||||||
-5 | Operating profit for the third quarter and first nine months of 2013 includes a $40 million charge for a legal dispute in our Canadian business, which was recorded in operating expenses. | |||||||||||||||
-6 | Technology Solutions segment results for the third quarter of 2014 include product alignment charges, integration-related expenses and reduction-in-workforce severance charges totaling $57 million, of which $34 million was recorded in cost of sales and $23 million was recorded in operating expenses. This segment’s results for the first nine months of 2014 include product alignment charges, integration-related expenses and reduction-in-workforce severance charges totaling $60 million, of which $34 million was recorded in cost of sales and $26 million was recorded in operating expenses. | |||||||||||||||
-7 | Corporate expenses, net for the third quarter and first nine months of 2014 include $25 million of acquisition-related expenses and for the first nine months of 2013 are net of an $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building. |
Business_Combinations_Narrativ
Business Combinations (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | ||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Feb. 22, 2013 | Feb. 28, 2013 | Feb. 22, 2013 | Dec. 31, 2013 | Jun. 30, 2013 | Apr. 06, 2012 | |
PSS World Medical [Member] | PSS World Medical [Member] | PSS World Medical [Member] | PSS World Medical [Member] | Corporate Headquarters [Member] | Corporate Headquarters [Member] | |||||
Amounts Recognized as of Acquisition Date as Adjusted [Member] | Amounts Recognized as of Acquisition Date as Adjusted [Member] | |||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Effective date of acquisition | ' | ' | ' | ' | ' | 22-Feb-13 | ' | ' | 6-Apr-12 | ' |
Name of acquired entity | ' | ' | ' | ' | 'PSS World Medical, Inc. (bPSS World Medicalb) | ' | ' | ' | ' | ' |
Description of acquired entity | ' | ' | ' | ' | 'PSS World Medical markets and distributes medical products and services throughout the United States | ' | ' | ' | ' | ' |
Per share price of outstanding shares acquired | ' | ' | ' | ' | $29 | ' | ' | ' | ' | ' |
Purchase price for acquisition | ' | ' | ' | ' | $1,900,000,000 | ' | ' | ' | ' | ' |
Cash paid for acquisition | ' | ' | ' | ' | ' | ' | 1,300,000,000 | ' | 90,000,000 | ' |
Current portion of long-term debt acquired | ' | ' | ' | ' | ' | ' | 600,000,000 | 635,000,000 | ' | ' |
Currently acquired percentage of building | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% |
Previously held percentage of building | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% |
Gain on business combination | 0 | 0 | 0 | 81,000,000 | ' | ' | ' | ' | 81,000,000 | ' |
Gain on business combination, net of tax | ' | ' | ' | ' | ' | ' | ' | ' | 51,000,000 | ' |
Fair value of assets acquired | ' | ' | ' | ' | ' | ' | ' | ' | ' | 180,000,000 |
Fair value of assets acquired, buildings | ' | ' | ' | ' | ' | ' | ' | ' | ' | 113,000,000 |
Fair value of assets acquired, land | ' | ' | ' | ' | ' | ' | ' | ' | ' | $58,000,000 |
Property, plant and equipment, useful life | ' | ' | ' | ' | ' | ' | ' | ' | '30 years | ' |
Business_Combinations_Fair_Val
Business Combinations (Fair Value Of Assets Acquired And Liabilities Assumed) (Details) (USD $) | Dec. 31, 2013 | Mar. 31, 2013 | Feb. 22, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Feb. 22, 2013 | |
In Millions, unless otherwise specified | PSS World Medical [Member] | PSS World Medical [Member] | PSS World Medical [Member] | PSS World Medical [Member] | |||
Amounts Previously Recognized as of Acquisition Date [Member] | Purchase Price Allocation Adjustments [Member] | Amounts Recognized as of Acquisition Date as Adjusted [Member] | Amounts Recognized as of Acquisition Date as Adjusted [Member] | ||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | |
Current assets, net of cash and cash equivalents acquired | ' | ' | $706 | [1] | $5 | $711 | ' |
Goodwill | 6,300 | 6,405 | 1,145 | [1] | -15 | 1,130 | ' |
Intangible assets | ' | ' | 557 | [1] | 11 | 568 | ' |
Other long-term assets | ' | ' | 183 | [1] | -1 | 182 | ' |
Current liabilities | ' | ' | -376 | [1] | 3 | -373 | ' |
Current portion of long-term debt acquired | ' | ' | -635 | [1] | 0 | -635 | -600 |
Other long-term liabilities | ' | ' | -281 | [1] | -3 | -284 | ' |
Net assets acquired, less cash and cash equivalents | ' | ' | $1,299 | [1] | $0 | $1,299 | ' |
[1] | As previously reported in our Form 10-K for the year ended March 31, 2013. |
Acquisition_of_Celesio_AG_Deta
Acquisition of Celesio AG (Details) | 0 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | 1 Months Ended | 0 Months Ended | |||||||||||||||||||||||
Oct. 24, 2013 | Oct. 24, 2013 | Dec. 31, 2013 | Jan. 13, 2014 | Jan. 23, 2014 | Jan. 23, 2014 | Jan. 31, 2014 | Jan. 09, 2014 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Nov. 30, 2013 | Oct. 31, 2013 | Nov. 30, 2013 | Oct. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Jan. 30, 2014 | Dec. 31, 2013 | Oct. 31, 2013 | Oct. 31, 2013 | Oct. 24, 2013 | Jan. 23, 2014 | Oct. 31, 2013 | Oct. 31, 2013 | Oct. 31, 2013 | Jan. 23, 2014 | Jan. 23, 2014 | Jan. 23, 2014 | Dec. 31, 2013 | |
Celesio [Member] | Celesio [Member] | Celesio [Member] | Minimum [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Operating expense [Member] | Interest expense [Member] | Other income (loss), net [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Options to purchase FX - not designated as hedge | Options to purchase FX - not designated as hedge | Options to purchase FX - not designated as hedge | Franz Haniel Cie GmbH [Member] | Franz Haniel Cie GmbH [Member] | 2013 Bridge Loan [Member] | 2013 Bridge Loan [Member] | 2013 Bridge Loan [Member] | 2014 Bridge Loan [Member] | 2014 Bridge Loan [Member] | 2014 Bridge Loan [Member] | 2014 Bridge Loan [Member] | |
USD ($) | EUR (€) | USD ($) | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | USD ($) | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | USD ($) | Maximum [Member] | Subsequent Event [Member] | Options held [Member] | Options held [Member] | Options held [Member] | Celesio [Member] | Subsequent Event [Member] | Celesio [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Revolving Credit Facility [Member] | |
country | USD ($) | EUR (€) | EUR (€) | USD ($) | USD ($) | USD ($) | Celesio [Member] | Celesio [Member] | Maximum [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Celesio [Member] | Maximum [Member] | Celesio [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Maximum [Member] | ||||||||||||
USD ($) | EUR (€) | USD ($) | Celesio [Member] | Celesio [Member] | Maximum [Member] | Celesio [Member] | |||||||||||||||||||||||||
USD ($) | Celesio [Member] | ||||||||||||||||||||||||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of countries in which entity operates | 14 | 14 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Date of acquisition agreement | 24-Oct-13 | 24-Oct-13 | ' | ' | ' | ' | 23-Jan-14 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Name of acquired entity | 'Celesio AG | 'Celesio AG | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of voting interests owned by individual seller | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.01% | 75.99% | ' | ' | ' | ' | ' | ' | ' |
Description of acquired entity | 'Celesio is an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. Celesio operates in 14 countries and is headquartered in Stuttgart, Germany. | 'Celesio is an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. Celesio operates in 14 countries and is headquartered in Stuttgart, Germany. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Per share price of outstanding shares acquired | ' | € 23 | ' | ' | ' | € 23.50 | ' | € 23.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Acquisition threshold, percentage ownership required to complete transaction | 75.00% | 75.00% | ' | 75.00% | 75.00% | 75.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Purchase price for acquisition | $8,300,000,000 | € 6,100,000,000 | ' | ' | $8,700,000,000 | € 6,400,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Foreign currency exchange rate, translation | 1.35 | 1.35 | ' | ' | 1.37 | 1.37 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Control Obtained Description | ' | ' | ' | ' | ' | ' | 'we entered into (i) an amendment to the BCA, (ii) an amended and restated SPA with Haniel, and (iii) a Bond Purchase Agreement with Elliott International, L.P., The Liverpool Limited Partnership and Elliott Capital Advisers, L.P. (collectively, the bAcquisitionb) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Bridge loan, maximum borrowing capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,350,000,000 | ' | ' | ' | ' | 1,300,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | 5,500,000,000 | ' | ' | 5,500,000,000 | ' | ' |
Term loan agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '364 days | ' | ' | '364 days | ' | ' | ' |
Derivative, notional amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,600,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative, foreign currency option strike price (usd per option) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.4 | 1.4 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative instruments not designated as hedging instruments, gain (loss), net | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ratio of indebtedness to net capital | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.65 | 0.565 | 0.65 | 0.565 | ' | 0.565 | 0.65 | ' | ' | ' | ' | ' | ' | ' | 0.65 | ' | ' | 0.65 | 0.565 |
Expenses related to acquisition | ' | ' | $35,000,000 | ' | ' | ' | ' | ' | $12,000,000 | $10,000,000 | $13,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Technology_Solutions_Charges_D
Technology Solutions Charges (Details) (Technology Solutions [Member], USD $) | 3 Months Ended | 9 Months Ended |
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2013 |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | $57 | $60 |
Cost of sales [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | 34 | 34 |
Operating expense [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | 23 | 26 |
Product alignment charges | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | 35 | ' |
Integration-related expenses [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | 15 | ' |
Reduction in workforce severance charges [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | 7 | ' |
Severance charges due to reorganization [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | 35 | ' |
Asset impairment charges [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Other nonrecurring expense | $15 | ' |
Sale_of_an_Equity_Investment_N
Sale of an Equity Investment (Narrative) (Details) (Distribution Solutions [Member], Nadro [Member], USD $) | 9 Months Ended |
In Millions, unless otherwise specified | Dec. 31, 2013 |
Distribution Solutions [Member] | Nadro [Member] | ' |
Schedule of Equity Method Investments [Line Items] | ' |
Sale of an equity investment, ownership percentage | 49.00% |
Proceeds from sale of equity investment | $41 |
Income_Taxes_Narrative_Details
Income Taxes (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended |
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2013 |
Income Tax [Line Items] | ' | ' |
Unrecognized tax benefits | $656 | $656 |
Unrecognized tax benefits that would impact income tax expense and the effective tax rate | 500 | 500 |
Potential reduction of unrecognized benefits due to audit resolutions and expiration of statutes of limitations | 227 | 227 |
Accrued interest and penalties on unrecognized tax benefits | 180 | 180 |
Income tax examination, penalties and interest expense | 44 | 50 |
Internal Revenue Service (IRS) [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Tax assessments received | ' | 98 |
Internal Revenue Service (IRS) [Member] | 2003 through 2006 [Member] | Minimum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2003 |
Internal Revenue Service (IRS) [Member] | 2003 through 2006 [Member] | Maximum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2006 |
Internal Revenue Service (IRS) [Member] | 2007 through 2009 [Member] | Minimum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2007 |
Internal Revenue Service (IRS) [Member] | 2007 through 2009 [Member] | Maximum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2009 |
Canada Revenue Agency Assessments [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Tax assessments received | ' | 210 |
Income Taxes Paid | ' | 156 |
Canada Revenue Agency Assessments [Member] | 2003 through 2008 [Member] | Minimum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2003 |
Canada Revenue Agency Assessments [Member] | 2003 through 2008 [Member] | Maximum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2008 |
Canada Revenue Agency Assessments [Member] | 2003 [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Year for which assessment is appealed | ' | '2003 |
Income Tax Benefit Discrete Items | $122 | ' |
Canada Revenue Agency Assessments [Member] | 2009 through 2013 [Member] | Minimum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2009 |
Canada Revenue Agency Assessments [Member] | 2009 through 2013 [Member] | Maximum [Member] | ' | ' |
Income Tax [Line Items] | ' | ' |
Income Tax, year under examination | ' | '2013 |
Discontinued_Operations_Narrat
Discontinued Operations (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' |
Proceeds from sale of business | ' | ' | $55 | $0 |
Assets of disposal group, including discontinued operation | 258 | ' | 258 | ' |
Liabilities of disposal group, including discontinued operation | 207 | ' | 207 | ' |
Loss on sale, before tax | -5 | 0 | -5 | 0 |
International Technology [Member] | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' |
Non-cash pre-tax impairment charge | 80 | ' | ' | ' |
Non-cash after-tax impairment charge | 80 | ' | ' | ' |
Hospital Automation [Member] | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' |
Proceeds from sale of business | 55 | ' | ' | ' |
Loss on sale, before tax | -5 | ' | ' | ' |
Loss on sale, after tax | ($7) | ' | ' | ' |
Discontinued_Operations_Schedu
Discontinued Operations (Schedule of Results from Discontinued Operations) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Discontinued Operations and Disposal Groups [Abstract] | ' | ' | ' | ' |
Revenues | $78 | $88 | $304 | $282 |
Loss from discontinued operations | -85 | -13 | -98 | -5 |
Loss on sale, before tax | -5 | 0 | -5 | 0 |
Loss from discontinued operations before income tax | -90 | -13 | -103 | -5 |
Income tax (expense) benefit | -2 | 5 | 3 | 0 |
Loss from discontinued operations, net of tax | ($92) | ($8) | ($100) | ($5) |
Earnings_Per_Common_Share_Narr
Earnings Per Common Share (Narrative) (Details) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Earnings Per Share [Abstract] | ' | ' | ' | ' |
Antidilutive securities excluded from computation of earnings per share, amount | 0 | 1 | 3 | 5 |
Earnings_Per_Common_Share_Basi
Earnings Per Common Share (Basic and Diluted Earnings per Common Share) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
In Millions, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ' | ' | ' | ' | ||||
Income from continuing operations | $156 | $306 | $992 | $1,084 | ||||
Loss from discontinued operations, net of tax | -92 | -8 | -100 | -5 | ||||
Net income | $64 | $298 | $892 | $1,079 | ||||
Weighted average common shares outstanding: | ' | ' | ' | ' | ||||
Basic | 230 | 235 | 229 | 236 | ||||
Effect of dilutive securities: | ' | ' | ' | ' | ||||
Diluted | 234 | 240 | 233 | 240 | ||||
Diluted | ' | ' | ' | ' | ||||
Continuing operations | $0.67 | [1] | $1.27 | [1] | $4.26 | [1] | $4.51 | [1] |
Discontinued operations | ($0.39) | [1] | ($0.03) | [1] | ($0.43) | [1] | ($0.02) | [1] |
Total | $0.28 | [1] | $1.24 | [1] | $3.83 | [1] | $4.49 | [1] |
Basic | ' | ' | ' | ' | ||||
Continuing operations | $0.68 | [1] | $1.30 | [1] | $4.34 | [1] | $4.60 | [1] |
Discontinued operations | ($0.40) | [1] | ($0.03) | [1] | ($0.44) | [1] | ($0.02) | [1] |
Total | $0.28 | [1] | $1.27 | [1] | $3.90 | [1] | $4.58 | [1] |
Options to purchase common stock [Member] | ' | ' | ' | ' | ||||
Effect of dilutive securities: | ' | ' | ' | ' | ||||
Dilutive securities | 2 | 1 | 1 | 1 | ||||
Restricted Stock Units [Member] | ' | ' | ' | ' | ||||
Effect of dilutive securities: | ' | ' | ' | ' | ||||
Dilutive securities | 2 | 4 | 3 | 3 | ||||
[1] | Certain computations may reflect rounding adjustments. |
Goodwill_And_Intangible_Assets2
Goodwill And Intangible Assets, Net (Changes In The Carrying Amount Of Goodwill) (Details) (USD $) | 9 Months Ended |
In Millions, unless otherwise specified | Dec. 31, 2013 |
Goodwill [Line Items] | ' |
Goodwill, beginning balance | $6,405 |
Goodwill acquired | 45 |
Amount reclassified to assets held-for-sale | -127 |
Foreign currency translation adjustments and other | -23 |
Goodwill, Ending Balance | 6,300 |
Distribution Solutions [Member] | ' |
Goodwill [Line Items] | ' |
Goodwill, beginning balance | 4,413 |
Goodwill acquired | 45 |
Amount reclassified to assets held-for-sale | 0 |
Foreign currency translation adjustments and other | -13 |
Goodwill, Ending Balance | 4,445 |
Technology Solutions [Member] | ' |
Goodwill [Line Items] | ' |
Goodwill, beginning balance | 1,992 |
Goodwill acquired | 0 |
Amount reclassified to assets held-for-sale | -127 |
Foreign currency translation adjustments and other | -10 |
Goodwill, Ending Balance | $1,855 |
Goodwill_And_Intangible_Assets3
Goodwill And Intangible Assets, Net Goodwill And Intangible Assets, Net (Narrative - Goodwill) (Details) (Technology Solutions [Member], USD $) | Dec. 31, 2013 | Mar. 31, 2013 |
In Millions, unless otherwise specified | ||
Technology Solutions [Member] | ' | ' |
Goodwill [Line Items] | ' | ' |
Accumulated goodwill impairment loss | $36 | $36 |
Goodwill_And_Intangible_Assets4
Goodwill And Intangible Assets, Net (Information Regarding Intangible Assets) (Details) (USD $) | 9 Months Ended | |
In Millions, unless otherwise specified | Dec. 31, 2013 | Mar. 31, 2013 |
Intangible assets | ' | ' |
Gross Carrying Amount | $3,292 | $3,347 |
Accumulated Amortization | -1,226 | -1,077 |
Net Carrying Amount | 2,066 | 2,270 |
Customer lists [Member] | ' | ' |
Intangible assets | ' | ' |
Weighted Average Remaining Amortization Period (years) | '7 years | ' |
Gross Carrying Amount | 1,791 | 1,761 |
Accumulated Amortization | -804 | -672 |
Net Carrying Amount | 987 | 1,089 |
Service agreements [Member] | ' | ' |
Intangible assets | ' | ' |
Weighted Average Remaining Amortization Period (years) | '17 years | ' |
Gross Carrying Amount | 999 | 1,018 |
Accumulated Amortization | -157 | -114 |
Net Carrying Amount | 842 | 904 |
Trademarks and trade names [Member] | ' | ' |
Intangible assets | ' | ' |
Weighted Average Remaining Amortization Period (years) | '16 years | ' |
Gross Carrying Amount | 201 | 208 |
Accumulated Amortization | -53 | -46 |
Net Carrying Amount | 148 | 162 |
Technology [Member] | ' | ' |
Intangible assets | ' | ' |
Weighted Average Remaining Amortization Period (years) | '4 years | ' |
Gross Carrying Amount | 215 | 271 |
Accumulated Amortization | -170 | -207 |
Net Carrying Amount | 45 | 64 |
Other [Member] | ' | ' |
Intangible assets | ' | ' |
Weighted Average Remaining Amortization Period (years) | '6 years | ' |
Gross Carrying Amount | 86 | 89 |
Accumulated Amortization | -42 | -38 |
Net Carrying Amount | $44 | $51 |
Goodwill_And_Intangible_Assets5
Goodwill And Intangible Assets, Net (Narrative - Intangible Assets) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ' | ' | ' |
Amortization expense of intangible assets | $70 | $52 | $211 | $147 |
Annual amortization expense, 2014 | 279 | ' | 279 | ' |
Annual amortization expense, 2015 | 261 | ' | 261 | ' |
Annual amortization expense, 2016 | 229 | ' | 229 | ' |
Annual amortization expense, 2017 | 207 | ' | 207 | ' |
Annual amortization expense, 2018 | 190 | ' | 190 | ' |
Total amortization expense, after 2018 | $1,111 | ' | $1,111 | ' |
Debt_and_Financing_Activities_
Debt and Financing Activities (Accounts Receivable Sales Facility and Revolving Credit Facility) (Narrative) (Details) (USD $) | 9 Months Ended | 1 Months Ended | 9 Months Ended | 9 Months Ended | ||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Nov. 30, 2013 | 31-May-13 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2013 | Nov. 30, 2013 | Oct. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2013 | Dec. 31, 2013 | Nov. 30, 2013 | Oct. 31, 2013 | Jan. 30, 2014 | |
Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Accounts Receivable Sales Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member] | |||
Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Revolving Credit Facility [Member] | |||||||||||
Maximum [Member] | ||||||||||||||||
Line of Credit Facility [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Repayments of lines of credit | ' | ' | ' | ' | $150,000,000 | $1,525,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accounts receivable sales facility, expiration period | ' | ' | '1 year | '6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ratio of indebtedness to net capital | ' | ' | ' | ' | ' | ' | ' | 0.65 | 0.565 | ' | ' | ' | 0.565 | ' | ' | 0.65 |
Credit facility capacity | ' | ' | ' | ' | 1,350,000,000 | ' | ' | ' | ' | 1,300,000,000 | ' | ' | ' | ' | ' | ' |
Facility expiration date | ' | ' | ' | ' | 15-Nov-14 | ' | ' | ' | ' | 23-Sep-16 | ' | ' | ' | ' | ' | ' |
Contingent ratio of indebtedness to net capital | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 65.00% | 56.50% | ' |
Credit facility, increase, additional borrowings | ' | ' | ' | ' | 150,000,000 | 1,125,000,000 | ' | ' | ' | 0 | 0 | ' | ' | ' | ' | ' |
Proceeds from short-term borrowings | 150,000,000 | 1,125,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Repayments of short-term borrowings | 150,000,000 | 1,525,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Borrowings outstanding | ' | ' | ' | ' | 0 | ' | 0 | ' | ' | 0 | ' | 0 | ' | ' | ' | ' |
Related securitized accounts receivable outstanding | ' | ' | ' | ' | $0 | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Hedging_Activities_Narrative_D
Hedging Activities (Narrative) (Details) (USD $) | 9 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2012 | Sep. 30, 2013 | |
Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Canada, Dollars | Canada, Dollars | Canada, Dollars | Canada, Dollars | Canada, Dollars | Canada, Dollars | Canada, Dollars | Canada, Dollars | United Kingdom, Pounds | Mexico, Pesos | ||
Derivative [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Notional Amount of Foreign Currency Derivatives | ' | $503,000,000 | ' | $503,000,000 | ' | $503,000,000 | $90,000,000 | $172,000,000 | $177,000,000 | $151,000,000 | $41,000,000 |
Derivative, Remaining Maturity | '8 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net | ' | $0 | $0 | $0 | $0 | ' | ' | ' | ' | ' | ' |
Fair_Value_Measurements_Narrat
Fair Value Measurements (Narrative) (Details) (USD $) | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | International Technology [Member] | International Technology [Member] | |||
Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Nonrecurring [Member] | ||||
Fair Value, Inputs, Level 3 [Member] | ||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Notes and Loans Payable | $4,900,000,000 | $4,900,000,000 | ' | ' | ' | ' | ' | ' |
Debt Instrument, Fair Value Disclosure | ' | ' | 5,100,000,000 | 5,500,000,000 | ' | ' | ' | ' |
Cash and Cash Equivalents, Fair Value Disclosure | ' | ' | ' | ' | 2,000,000,000 | 1,600,000,000 | ' | ' |
Non-cash pre-tax impairment charge | ' | ' | ' | ' | ' | ' | $80,000,000 | $80,000,000 |
Commitments_and_Contingent_Lia2
Commitments and Contingent Liabilities (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Loss Contingencies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation charges | $18,000,000 | ' | ' | $0 | ' | ' | $68,000,000 | $60,000,000 |
Average Wholesale Price Litigation [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Loss Contingencies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation charges | $18,000,000 | $35,000,000 | $15,000,000 | $0 | $44,000,000 | $16,000,000 | $68,000,000 | $60,000,000 |
Commitments_and_Contingent_Lia3
Commitments and Contingent Liabilities (Litigation Reserve and Expense) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Loss Contingencies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Charges incurred | $18,000,000 | ' | ' | $0 | ' | ' | $68,000,000 | $60,000,000 |
Payments made | ' | ' | ' | ' | ' | ' | -86,000,000 | -470,000,000 |
Average Wholesale Price Litigation [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Loss Contingencies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
AWP litigation reserve at beginning of period | ' | ' | 42,000,000 | ' | ' | 453,000,000 | 42,000,000 | 453,000,000 |
Charges incurred | 18,000,000 | 35,000,000 | 15,000,000 | 0 | 44,000,000 | 16,000,000 | 68,000,000 | 60,000,000 |
Payments made | ' | ' | ' | ' | ' | ' | -86,000,000 | -470,000,000 |
AWP litigation reserve at end of period | $24,000,000 | ' | ' | $43,000,000 | ' | ' | $24,000,000 | $43,000,000 |
Stockholders_Equity_Narrative_
Stockholders' Equity (Narrative) (Details) (USD $) | 9 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 4 Months Ended | 1 Months Ended | |||
In Millions, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Apr. 22, 2013 | Mar. 31, 2013 | Mar. 31, 2013 | Apr. 22, 2013 | Jul. 31, 2013 | Jul. 31, 2013 |
Distribution Solutions [Member] | ASR March 2013 [Member] | ASR March 2013 [Member] | ASR March 2013 [Member] | ASR March 2013 [Member] | Old Rate Per Share [Member] | New Rate Per Share [Member] | |||
Nadro [Member] | |||||||||
Stockholders' Equity [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Dividends rate per share | ' | ' | ' | ' | ' | ' | ' | $0.20 | $0.24 |
Payments for repurchase of common stock | $128 | $413 | ' | ' | ' | $150 | ' | ' | ' |
Shares received under repurchase programs | ' | ' | ' | 0.2 | 1.2 | ' | 1.4 | ' | ' |
Average price paid per share | ' | ' | ' | ' | ' | ' | $107.63 | ' | ' |
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $340 | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of an equity investment, ownership percentage | ' | ' | 49.00% | ' | ' | ' | ' | ' | ' |
Stockholders_Equity_Other_Comp
Stockholders' Equity (Other Comprehensive Income (Loss), Net of Tax) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | ||||
Stockholders' Equity Attributable to Parent [Abstract] | ' | ' | ' | ' | ||||
Foreign currency translation adjustments arising during period, net of income tax expense (benefit) of nil, ($4), nil and ($2) | ($55) | ($16) | ($60) | $14 | ||||
Reclassified to income statement, net of income tax expense of nil, nil, $24 and nil (1) | 0 | [1] | 0 | [1] | 44 | [1] | 0 | [1] |
Foreign currency translation adjustments, net of income tax expense (benefit) of nil, ($4), $24 and ($2) | -55 | -16 | -16 | 14 | ||||
Unrealized gains (losses) on cash flow hedges arising during period, net of income tax expense of nil, nil, nil and nil | -1 | 0 | -2 | 2 | ||||
Amortization of actuarial loss, prior service cost and transition obligation, net of income tax expense of $4, $3, $10 and $8 (2) | 3 | [2] | 5 | [2] | 16 | [2] | 14 | [2] |
Foreign currency translation adjustments, net of income tax expense of nil, nil, nil and nil | 1 | 0 | -2 | 0 | ||||
Reclassified to income statement, net of income tax expense of nil, nil, $1 and nil | 0 | 0 | 1 | 0 | ||||
Retirement-related benefit plans, net of income tax expense of $4, $3, $11 and $8 | 4 | 5 | 15 | 14 | ||||
Other Comprehensive Income (Loss), net of tax | ($52) | ($11) | ($3) | $30 | ||||
[1] | As a result of our sale of our 49% equity interest in Nadro, foreign currency translation net losses of $44 million were reclassified from AOCI to other income, within our condensed consolidated statement of operations. Such losses were previously considered in our impairment evaluation of the investment when we committed to a plan to sell the investment during the fourth quarter of 2013, and accordingly did not impact the 2014 earnings period for the third quarter and first nine months of 2014. | |||||||
[2] | Pre-tax amount was reclassified into cost of sales and operating expenses in the condensed consolidated statements of operations. The related tax expense (benefit) was reclassified into income tax expense in the condensed consolidated statements of operations. |
Stockholders_Equity_Other_Comp1
Stockholders' Equity (Other Comprehensive Income (Loss), Net of Tax) (Parentheticals) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 |
Stockholders' Equity Attributable to Parent [Abstract] | ' | ' | ' | ' |
Foreign currency translation adjustments arising during period, income tax expense (benefit) of nil, ($4), nil and ($2) | $0 | ($4) | $0 | ($2) |
Reclassified to income statement, income tax expense of nil, nil, $24 and nil | 0 | 0 | 24 | 0 |
Unrealized gains (losses) on cash flow hedges arising during period, income tax expense of nil, nil, nil and nil | 0 | 0 | 0 | 0 |
Amortization of actuarial loss, prior service cost and transition obligation, income tax expense of $4, $3, $10 and $8 | 4 | 3 | 10 | 8 |
Foreign currency translation adjustments, income tax expense of nil, nil, nil and nil | 0 | 0 | 0 | 0 |
Reclassified to income statement, income tax expense of nil, nil, $1 and nil | $0 | $0 | $1 | $0 |
Stockholders_Equity_Changes_in
Stockholders' Equity (Changes in Accumulated Other Comprehensive Income (Loss) by Component) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
In Millions, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | ||||
Stockholders' Equity Attributable to Parent [Abstract] | ' | ' | ' | ' | ||||
Foreign Currency Translation Adjustments, Net of Tax, Beginning Balance | ' | ' | $136 | ' | ||||
Other comprehensive income (loss) before reclassifications, Foreign Currency Translation Adjustments, | -55 | -16 | -60 | 14 | ||||
Amounts reclassified to earnings, Foreign Currency Translation Adjustments, Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax | 0 | [1] | 0 | [1] | 44 | [1] | 0 | [1] |
Foreign currency translation adjustments | -55 | -16 | -16 | 14 | ||||
Foreign Currency Translation Adjustments, Net of Tax, Ending Balance | 120 | ' | 120 | ' | ||||
Unrealized Losses on Cash Flow Hedges, Net of Tax, Beginning Balance | ' | ' | -5 | ' | ||||
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax | -1 | 0 | -2 | 2 | ||||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax | ' | ' | 0 | ' | ||||
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax | -1 | 0 | -2 | 2 | ||||
Unrealized Losses on Cash Flow Hedges, Net of Tax, Ending Balance | -7 | ' | -7 | ' | ||||
Unrealized net loss and other components of benefit plans, net of tax, beginning balance | ' | ' | -196 | ' | ||||
Other Comprehensive Income Translation Impact On Pension Plans, Net Of Tax | ' | ' | 14 | ' | ||||
Other Comprehensive (Income) Loss, Total Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax | 0 | 0 | 1 | 0 | ||||
Retirement-related benefit plans, net of income tax expense of $4, $3, $11 and $8 | 4 | 5 | 15 | 14 | ||||
Unrealized net loss and other components of benefit plans, net of tax, ending balance | -181 | ' | -181 | ' | ||||
Total Accumulated Other Comprehensive Income (Loss), Beginning Balance | ' | ' | -65 | ' | ||||
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax | ' | ' | -48 | ' | ||||
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | ' | ' | 45 | ' | ||||
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | -52 | -11 | -3 | 30 | ||||
Total Accumulated Other Comprehensive Income (Loss), Ending Balance | ($68) | ' | ($68) | ' | ||||
[1] | As a result of our sale of our 49% equity interest in Nadro, foreign currency translation net losses of $44 million were reclassified from AOCI to other income, within our condensed consolidated statement of operations. Such losses were previously considered in our impairment evaluation of the investment when we committed to a plan to sell the investment during the fourth quarter of 2013, and accordingly did not impact the 2014 earnings period for the third quarter and first nine months of 2014. |
Segment_Information_Narrative_
Segment Information (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation charges | $18,000,000 | ' | ' | $0 | ' | ' | $68,000,000 | $60,000,000 |
Charges associated with last-in-first-out inventory method | ' | ' | ' | ' | ' | ' | 186,000,000 | 5,000,000 |
Gain on business combination | 0 | ' | ' | 0 | ' | ' | 0 | 81,000,000 |
Average Wholesale Price Litigation [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation charges | 18,000,000 | 35,000,000 | 15,000,000 | 0 | 44,000,000 | 16,000,000 | 68,000,000 | 60,000,000 |
Distribution Solutions [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Revenue Derived From Services | 'less than 2% | ' | ' | 'less than 2% | ' | ' | 'less than 2% | 'less than 2% |
Distribution Solutions [Member] | Operating expense [Member] | RAMQ [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation charges | ' | ' | ' | 40,000,000 | ' | ' | ' | 40,000,000 |
Distribution Solutions [Member] | Operating expense [Member] | Average Wholesale Price Litigation [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation charges | 18,000,000 | ' | ' | ' | ' | ' | 68,000,000 | 60,000,000 |
Distribution Solutions [Member] | Cost of sales [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Charges associated with last-in-first-out inventory method | 142,000,000 | ' | ' | 2,000,000 | ' | ' | 186,000,000 | 5,000,000 |
Corporate Segment [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Gain on business combination | ' | ' | ' | ' | ' | ' | ' | 81,000,000 |
Antitrust Class Action Lawsuit [Member] | Distribution Solutions [Member] | Cost of sales [Member] | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Litigation Settlement, Amount | $27,000,000 | ' | ' | $8,000,000 | ' | ' | $34,000,000 | $27,000,000 |
Segment_Information_Schedule_o
Segment Information (Schedule of Segment Information) (Details) (USD $) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Jun. 30, 2013 | Apr. 06, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |||||||||||||
Reportable Segment [Member] | Reportable Segment [Member] | Reportable Segment [Member] | Reportable Segment [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions Domestic Pharmaceutical Distribution And Services [Member] | Distribution Solutions Domestic Pharmaceutical Distribution And Services [Member] | Distribution Solutions Domestic Pharmaceutical Distribution And Services [Member] | Distribution Solutions Domestic Pharmaceutical Distribution And Services [Member] | Distribution Solutions Direct Distribution And Services [Member] | Distribution Solutions Direct Distribution And Services [Member] | Distribution Solutions Direct Distribution And Services [Member] | Distribution Solutions Direct Distribution And Services [Member] | Distribution Solutions Sales To Customers Warehouses [Member] | Distribution Solutions Sales To Customers Warehouses [Member] | Distribution Solutions Sales To Customers Warehouses [Member] | Distribution Solutions Sales To Customers Warehouses [Member] | Distribution Solutions Canada Pharmaceutical Distribution And Services [Member] | Distribution Solutions Canada Pharmaceutical Distribution And Services [Member] | Distribution Solutions Canada Pharmaceutical Distribution And Services [Member] | Distribution Solutions Canada Pharmaceutical Distribution And Services [Member] | Distribution Solutions Medical Surgical Distribution And Services [Member] | Distribution Solutions Medical Surgical Distribution And Services [Member] | Distribution Solutions Medical Surgical Distribution And Services [Member] | Distribution Solutions Medical Surgical Distribution And Services [Member] | Technology Solutions [Member] | Technology Solutions [Member] | Technology Solutions [Member] | Technology Solutions [Member] | Technology Solutions Services [Member] | Technology Solutions Services [Member] | Technology Solutions Services [Member] | Technology Solutions Services [Member] | Technology Solutions Software [Member] | Technology Solutions Software [Member] | Technology Solutions Software [Member] | Technology Solutions Software [Member] | Technology Solutions Hardware [Member] | Technology Solutions Hardware [Member] | Technology Solutions Hardware [Member] | Technology Solutions Hardware [Member] | Corporate Segment [Member] | Corporate Segment [Member] | Corporate Segment [Member] | Corporate Segment [Member] | Cost of sales [Member] | Cost of sales [Member] | Operating expense [Member] | Operating expense [Member] | RAMQ [Member] | RAMQ [Member] | Corporate Headquarters [Member] | Corporate Headquarters [Member] | Antitrust Class Action Lawsuit [Member] | Antitrust Class Action Lawsuit [Member] | Antitrust Class Action Lawsuit [Member] | Antitrust Class Action Lawsuit [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | |||||||||||||||||
Technology Solutions [Member] | Technology Solutions [Member] | Technology Solutions [Member] | Technology Solutions [Member] | Operating expense [Member] | Operating expense [Member] | Cost of sales [Member] | Cost of sales [Member] | Cost of sales [Member] | Cost of sales [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | Distribution Solutions [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Litigation Settlement, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $27,000,000 | $8,000,000 | $34,000,000 | $27,000,000 | ' | ' | ' | ' | ||||||||||||
Litigation charges | 18,000,000 | 0 | 68,000,000 | 60,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40,000,000 | 40,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Other nonrecurring expense | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 57,000,000 | ' | 60,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,000,000 | 34,000,000 | 23,000,000 | 26,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Expenses related to acquisition | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,000,000 | ' | 25,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Segment Reporting Revenue From External Customers | 34,306,000,000 | 31,099,000,000 | 99,468,000,000 | 91,553,000,000 | ' | ' | ' | ' | 33,522,000,000 | [1] | 30,361,000,000 | [1] | 97,094,000,000 | [1] | 89,347,000,000 | [1] | 29,275,000,000 | 26,854,000,000 | 84,824,000,000 | 79,246,000,000 | 24,859,000,000 | 22,386,000,000 | 71,620,000,000 | 64,625,000,000 | 4,416,000,000 | 4,468,000,000 | 13,204,000,000 | 14,621,000,000 | 2,785,000,000 | 2,633,000,000 | 7,984,000,000 | 7,559,000,000 | 1,462,000,000 | 874,000,000 | 4,286,000,000 | 2,542,000,000 | 784,000,000 | 738,000,000 | 2,374,000,000 | 2,206,000,000 | 658,000,000 | 598,000,000 | 1,975,000,000 | 1,777,000,000 | 107,000,000 | 120,000,000 | 338,000,000 | 357,000,000 | 19,000,000 | 20,000,000 | 61,000,000 | 72,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
Operating profit (2) (3) (4) (5) | ' | ' | ' | ' | 589,000,000 | 617,000,000 | 2,125,000,000 | 1,920,000,000 | 552,000,000 | [2],[3],[4],[5] | 525,000,000 | [2],[3],[4],[5] | 1,856,000,000 | [2],[3],[4],[5] | 1,646,000,000 | [2],[3],[4],[5] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 37,000,000 | [6] | 92,000,000 | [6] | 269,000,000 | [6] | 274,000,000 | [6] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -112,000,000 | [7] | -109,000,000 | [7] | -307,000,000 | [7] | -212,000,000 | [7] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest Expense | -69,000,000 | -59,000,000 | -187,000,000 | -170,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Income Before Income Taxes from Continuing Operations | 408,000,000 | 449,000,000 | 1,631,000,000 | 1,538,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Document Fiscal Year Focus | ' | ' | '2014 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Gain on business combination | $0 | $0 | $0 | $81,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $81,000,000 | ' | ' | ' | ' | ' | ' | $81,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Currently acquired percentage of building | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Percentage of Revenue Derived From Services | ' | ' | ' | ' | ' | ' | ' | ' | 'less than 2% | 'less than 2% | 'less than 2% | 'less than 2% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||||||
Percentage of service revenue | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.00% | 2.00% | 2.00% | 2.00% | ||||||||||||
[1] | Revenues derived from services represent less than 2% of this segmentbs total revenues. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[2] | Operating profit for the third quarter and first nine months of 2014 includes the receipt of $27 million and $34 million and for the third quarter and first nine months of fiscal year 2013 the receipt of $8 million and $27 million representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers, which was recorded as a reduction to cost of sales. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[3] | Operating profit for the third quarter and first nine months of 2014 includes last-in-first-out (bLIFOb) charges of $142 million and $186 million and, for the third quarter and first nine months of 2013 includes LIFO charges of $2 million and $5 million, which were recorded in cost of sales. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[4] | Operating profit for the third quarter and first nine months of 2013 includes a $40 million charge for a legal dispute in our Canadian business, which was recorded in operating expenses. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[5] | Operating profit for the third quarter of 2014 includes AWP litigation charges of $18 million and for the first nine months of 2014 and 2013 includes AWP litigation charges of $68 million and $60 million, which were recorded in operating expenses. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[6] | Technology Solutions segment results for the third quarter of 2014 include product alignment charges, integration-related expenses and reduction-in-workforce severance charges totaling $57B million, of which $34 million was recorded in cost of sales and $23 million was recorded in operating expenses. This segmentbs results for the first nine months of 2014 include product alignment charges, integration-related expenses and reduction-in-workforce severance charges totaling $60 million, of which $34 million was recorded in cost of sales and $26 million was recorded in operating expenses. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[7] | Corporate expenses, net for the third quarter and first nine months of 2014 include $25 million of acquisition-related expenses and for the first nine months of 2013 are net of an $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership interest in our corporate headquarters building. |